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ABSTRACT 
 
The occurrence of gestational diabetes (GDM) during pregnancy is a powerful sign of a risk of later 
type 2 diabetes (T2D) and cardiovascular diseases (CVDs). The physiological basis for this disease 
progression is not yet fully understood, but increasing evidence exists on interplay of insulin 
resistance, subclinical inflammation, and more recently, on unbalance of the autonomic nervous 
system. Since the delay in development of T2D and CVD after GDM ranges from years to decades, 
better understanding of the pathophysiology of GDM could give us new tools for primary 
prevention.  
 
The present study was aimed at investigating the role of the sympathetic nervous system (SNS) in 
GDM and its associations with insulin and a variety of inflammatory cytokines and coagulation and 
fibrinolysis markers. We hypothesized that the SNS is activated in pregnancy complicated by GDM 
when compared with normal pregnancy and that this activation is associated with changes in low-
grade tissue inflammation and coagulation. We further hypothesized that by reducing SNS activity 
it would be possible to improve the inflammatory profile in women at risk.      
 
This thesis covers two separate study lines. Firstly, we investigated 41 women with GDM and 22 
healthy pregnant and 14 non-pregnant controls during the night in hospital. Blood samples were 
drawn at 24:00, 4:00 and 7:00 h to determine the concentrations of plasma glucose, insulin, 
noradrenaline (NA) and adrenomedullin, markers of subclinical inflammation (C-reactive protein, 
interleukin-6, insulin-like growth factor-1, serum amyloid A, sex hormone-binding globulin, acid 
alpha-1 glycoprotein and cortisol), coagulation and fibrinolysis variables (thrombin time, 
thromboplastin time, activated partial thromboplastin time, factor VIII, fibrinogen, von Willebrand 
factor antigen, ristocetin cofactor activity and collagen binding activity as well as D-dimer) and 
platelet function. Overnight holter ECG recording was performed for analysis of heart rate 
variability (HRV). Secondly, we studied 87 overweight hypertensive women with natural 
menopause. They were randomised to use a central sympatholytic agent, moxonidine (0.3mg twice 
daily), the β-blocking agent atenolol (50 mg once daily+blacebo once daily) for 8 weeks. 
Inflammatory markers (C-reactive protein, tumour necrosis factor alpha [TNFα] and its receptor II, 
and interleukin-6) and adiponectin were analysed at the beginning and after 8 weeks. 
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Activation of the SNS (increase in NA, decreased HRV) was seen in pregnant vs. non-pregnant 
women, but no difference existed between GDM and normal pregnancy. However, modulation 
(internal rhythm) of HRV was attenuated in GDM. Insulin and inflammatory cytokine levels were 
comparable in all pregnant women but nocturnal variation of concentrations of C-reactive protein, 
serum amyloid A and insulin were reduced in GDM. Levels of coagulation factor VIII were lower 
in GDM compared with normal pregnancy, whereas no other differences were seen in coagulation 
and fibrinolysis markers. No significant associations were seen between NA and the studied 
parameters.  
 
In the study of postmenopausal women, moxonidine treatment was associated with favourable 
changes in the inflammatory profile, seen as a decrease in TNFα concentrations (increase in 
atenolol group) and preservation of adiponectin levels (decrease in atenolol group). 
 
In conclusion, our results did not support our hypotheses of increased SNS activity in GDM or a 
marked association between NA and inflammatory and coagulation markers. Reduced biological 
variation of HRV, insulin and inflammatory cytokines suggests disturbance of autonomic and 
hormonal regulatory mechanisms in GDM. This is a novel finding.  Further understanding of the 
regulatory mechanisms could allow earlier detection of risk women and the possibility of 
prevention.  In addition, our results support consideration of the SNS as one of the therapeutic 
targets in the battle against metabolic diseases, including T2D and CVD.   
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FINNISH SUMMARY 
 
Raskausdiabetes on varhainen merkki naisen lisääntyneestä tyypin 2 diabeteksen sekä sydän- ja 
verisuonitautien riskistä. Tähän taudinkehitykseen vaikuttavat nykykäsityksen mukaan 
insuliiniresistenssi ja lievä kudostulehdus. Viime aikoina on kiinnitetty yhä enemmän huomiota 
myös häiriöön autonomisen hermoston toiminnassa. Koska raskausdiabetes esiintyy vuosia tai jopa 
vuosikymmeniä ennen tyypin 2 diabeteksen ja sydän- ja verisuontautien ilmaantumista, 
raskausdiabeteksen patofysiologian parempi tunteminen voisi avata uusia mahdollisuuksia näiden 
sairauksien ehkäisyyn.  
 
Tämän väitöstutkimuksen tarkoituksena oli selvittää sympaattisen hermoston toimintaa 
raskausdiabeteksessa sekä sen yhteyksiä sokeriaineenvaihduntaan, tulehdukseen ja 
hyytymisjärjestelmään. Hypoteesimme oli, että raskausdiabetekseen liittyy sympaattisen hermoston 
aktivaatio, joka heijastuu tulehdus- ja hyytymistekijöihin. Lisäksi tutkimme, voidaanko 
sympaattisen hermoston aktivaatiota vähentämällä vaikuttaa suotuisasti tulehdukseen naisilla, joilla 
on lisääntynyt sydän- ja verisuonisairauksien riski. 
 
Väitöskirja koostuu kahdesta erillisestä tutkimuslinjasta. Ensimmäisessä tutkimuksessa 41 
raskausdiabeetikolle, 22 terveelle raskaana olevalle sekä 14:lle ei-raskaana olevalle naiselle tehtiin 
yöllinen EKG-nauhoitus sydämen autonomisen säätelyn tutkimista varten (sykevaihteluanalyysi). 
Lisäksi heiltä määritettiin veren glukoosi- ja insuliinipitoisuus, noradrenaliini ja adrenomedulliini, 
tietyt tulehdusmerkkiaineet (C-reaktiivinen proteiini eli CRP, interleukiini-6, insuliinikasvutekijä-1, 
amyloidi A, sukupuolihormoneja sitova globuliini, alfa1-glykoproteiini ja kortisoli), tietyt 
hyytymisaktivaation merkkiaineet (trombiiniaika, tromboplastiiniaika, aktivoitu partiaalinen 
tromboplastiiniaika, hyytymistekijä VIII, fibrinogeeni, von Willebrandin tekijän antigeeni, 
ristosetiinin aktiivisuus ja kollageenin sitomisaktiivisuus sekä D-dimeeri) ja verihiutaleaktivaatio. 
Toisessa tutkimuksessa 87 vaihdevuosi-ikäistä verenpainetta sairastavaa ylipainoista naista 
satunnaistettiin saamaan kahdeksan viikon ajan joko keskushermoston kautta sympaattisen 
hermoston toimintaa hillitsevää verenpainelääkettä moksonidiinia (0,3 mg kahdesti päivässä) tai 
beetasalpaajaa atenololia (50 mg kerran päivässä + lumepilleri). Tutkimuksen alussa ja lopussa 
määritettiin tietyt tulehdusmerkkiaineet (CRP, tuumorinekroositekijä alfa eli TNF-α  ja sen reseptori 
II, interleukiini-6 ja adiponektiini).  
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Havaitsimme sympaattisen hermoston aktivoituvan raskauden aikana: noradrenaliinin pitoisuus 
kasvoi ja sykevaihtelu väheni. Raskausdiabetesryhmän ja normaalin raskauden ryhmän välillä ei 
kuitenkaan ollut eroa. Rytmisen sykevaihtelun sen sijaan todettiin raskausdiabeteksessa 
vähentyneen verrokkiryhmiin nähden. Insuliini- ja tulehdusmerkkiainepitoisuuksissa ei havaittu 
eroja raskausdiabetesryhmän ja normaalin raskauden ryhmän välillä, mutta raskausdiabeteksessa 
todettiin insuliinin, CRP:n ja amyloidi A:n vähentynyt yöllinen vaihtelu. Noradrenaliinin ja 
tutkittujen muuttujien välillä ei havaittu merkitseviä yhteyksiä. 
 
Lääketutkimuksessamme tuli esiin moksonidiiniryhmässä suotuisa tulehdusprofiilin muutos 
verrattuna atenololiryhmään. Moksonidiinia saaneilla naisilla haitallinen TNF-α-pitoisuus pieneni, 
kun taas atenololiryhmässä pitoisuus kasvoi. Suojaavan adiponektiinin pitoisuus pysyi näillä naisilla 
ennallaan, mutta atenololiryhmässä tapahtui merkittävä lasku.  
  
Väitöstutkimuksen tulokset eivät siis tukeneet asetettuja hypoteeseja lisääntyneestä sympaattisen 
hermoston aktivaatiosta raskausdiabeteksessa eivätkä sympaattisen hermoston, inflammaation ja 
veren hyytymistekijöiden välittömistä yhteyksistä. Vähentynyt syketaajuuden, insuliinin ja 
tulehdusmerkkiaineiden biologinen vaihtelu raskausdiabeteksessa viittaa autonomisen hermoston ja 
aineenvaihdunnan säätelyn häiriintymiseen. Nämä havainnot ovat uusia. Taustalla olevien 
säätelymekanismien tarkempi tunteminen voi tulevaisuudessa tarjota uusia mahdollisuuksia tyypin 
2 diabeteksen ennaltaehkäisyyn. Lisäksi tutkimustulostemme mukaan sympaattinen hermosto voisi 
olla tulevaisuudessa yksi hoidon kohteista kamppailtaessa tyypin 2 diabeteksen ja sydän- ja 
verisuonitautien kaltaisia metabolisia sairauksia vastaan.  
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INTRODUCTION 
 
Coronary artery disease (CAD) is the most common cause of death in women in the Western world. 
Atherosclerosis typically develops, progresses and festers for decades in a clinically silent fashion, 
finally manifesting itself in a life-threatening catastrophe. Because of this treacherous development, 
various strategies to identify individuals at risk have been suggested (Ambrose and Srikanth 2010). 
Recent meta-analysis and randomized trial data indicate that global CAD risk information and 
aggressive multimodal therapy targeting the modifiable cardiovascular risk factors might contribute 
to improved prevention and reduction in the occurrence of adverse cardiovascular events (Sheridan 
et al. 2010, Mosca et al. 2007, Yusuf et al. 2004).  
 
The aetiopathogenesis of CAD is multifactorial, affected by lipid and lipoprotein changes, 
hypertension and metabolic factors, such as elevated blood glucose concentrations and various 
modified (oxidation, glycation) proteins (Bucala et al. 1994). Increased production of 
procoagulants, adhesion molecules, chemotactic factors and cytokines further contributes to this 
development. Even though the mechanisms behind these deleterious changes are multiple and 
complexly interrelated, some key elements of pathogenesis can be identified. Harmful inflammation 
seems to be a central denominator. Subclinical inflammation independently predicts adverse 
cardiovascular events and progression of coronary atherosclerosis (Nissen et al. 2004). The 
inflammatory system is closely related to the renin-angiotensin system (RAS) and the autonomic 
regulatory system, especially the sympathetic nervous system (SNS). In unfavourable conditions 
this crosstalk seems to create a vicious circle favouring the development of atherosclerosis. The 
connections demonstrated between the inflammatory system, coagulation and the autonomic 
nervous system are presented in Figure 1.    
 
Type 2 diabetes (T2D) has been considered to be a CAD risk equivalent to a >20% risk of 
developing a new major coronary event within 10 years following diagnosis (Haffner et al. 1998). 
One of the most powerful early predictors of T2D is gestational diabetes mellitus (GDM), which 
refers to glucose intolerance with onset or first recognition during pregnancy. Up to 70% of women 
with GDM develop T2D within 10 years after pregnancy (Kim et al. 2002). GDM is characterized 
by both pronounced insulin resistance and inflammation compared with normal pregnancy (Volpe 
et al. 2007, Barbour et al. 2007, Challis et al. 2009, Metzger et al. 2007). Much less is known about 
the function of the autonomic nervous system (ANS) and coagulation in GDM.  
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This thesis concerns investigation of SNS activity in GDM and associations between the SNS, 
inflammation and coagulation. Better understanding of the pathogenesis of GDM is mandatory in 
the aim to build new strategies for prevention of metabolic diseases after GDM.      
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Figure 1. Connections demonstrated between the SNS, inflammation and coagulation. 
Figure modified from Elenkov et al. 2000. 
 
NA, noradrenaline; TF, tissue factor; vWF, 
von Willebrand factor, FVIII, factor VIII; 
tPA, tissue plasminogen activator 
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REVIEW OF THE LITERATURE 
 
Autonomic nervous system                                             
 
The autonomic nervous system (ANS) controls (acting below the level of consciousness) visceral 
functions of the body. These functions include the automatism of the heart, blood pressure, 
respiration rate, digestion, salivation, perspiration, micturition and sexual arousal. The ANS is 
divided into three subsystems: the sympathetic nervous system (SNS), the parasympathetic nervous 
system (PNS), also called the vagal system, and the enteric nervous system, which is integral in 
autonomic function, particularly in the gut and the lungs.   
 
Anatomy and functions 
 
The function of the ANS is organized on the basis of reflex arcs comprising a visceral receptor, an 
afferent pathway, the central nervous system (CNS), an efferent pathway and the effector organ. 
Baroreceptors and chemoreceptors in the viscera monitor arterial pressure as well as the levels of 
multiple substances and chemicals, such as carbon dioxide, oxygen and glucose. Input from these 
receptors is integrated in regulation centres in the CNS for constant modulation of the activity of the 
efferent neurons. The efferent autonomic nerves consist of preganglionic and postganglionic 
neurons with synapses in autonomic ganglia which in the SNS are localized close to the spinal cord 
and in the PNS in or near the innervated organ. The postganglionic neurons innervate the effector 
organs (Figure 2). Acetylcholine is the preganglionic neurotransmitter for both the SNS and the 
PNS. At the effector organs, the PNS uses chiefly acetylcholine, whereas sympathetic neurons 
release noradrenaline (NA) to act mainly on α- and β- adrenergic receptors (ARs) (Soinila 2006). 
 
The SNS and the PNS typically function reciprocally. Their functions should, however, be regarded 
as complementary rather than antagonistic in the effort to achieve homeostasis. The SNS typically 
functions in actions requiring quick responses (‘fight or flight’). It is responsible for overall 
activation and energy generation in the body. When activated, the SNS enhances blood flow to 
critical organs, such as skeletal muscles (locomotion), the liver (energy supply) and the lungs 
(oxygen supply). When the situation lapses, the PNS promotes a return to a resting tone (‘rest and 
digest’). Functions of the SNS and the PNS in specific organs are summarized in Table 1.  
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Figure 2.   The autonomic nervous system reflex arc. 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
Assessment of ANS function 
 
Because of the complexity of the ANS, no single method exists in assessment of its functions. In 
addition, ANS responses typically show regional or organ-specific differentiation, with varying 
activities of the SNS and the PNS depending on the organ examined. Even though some tests 
provide data to assess the SNS specifically, the clinical outcome always reflects the balance 
between the SNS and PNS.    
 
Plasma noradrenaline  
Noradrenaline (NA) works both as a neurotransmitter in the CNS and as a hormone, released by the 
adrenal gland together with adrenaline. Measurement of NA concentration in venous blood 
represents one of the most commonly employed indexes of sympathetic activity in man. 
Reproducibility and sensitivity of this method in non-standardized conditions are limited, however, 
although reproducibility can be improved by repeated sampling (Grassi et al. 2009). In addition, 
discrimination between changes in secretion and/or clearance is not possible. In clinical studies and 
Effector organ 
Visceral receptor 
Postganglionic 
neuron 
Autonomic ganglia 
Preganglionic neuron 
CNS connections 
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in well-defined conditions, plasma NA levels seem to correlate relatively well with more specific 
SNS assessment methods (Kaaja and Pöyhönen-Alho 2006).     
 
 
Table 1. Actions of the sympathetic and the parasympathetic nervous systems. 
 
ORGAN SYMPATHETIC PARASYMPATHETIC 
Heart                                    
heart rate                        
contractility 
                                             
increases                                
increases 
                                           
decreases                         
decreases 
 
Blood vessels: arteries      
kidneys, viscera, skin, brain 
coronaries, larger                                   
coronaries, smaller,         
salivary gland, erectile tissue   
 liver, skeletal muscle 
                         veins 
constricts                            
constricts                                 
dilates                                 
constricts                                 
dilates                           
constricts/dilates 
no effect                                      
no effect                                      
no effect                               
dilates                                         
no effect   
no effect 
Bronchioles relaxes (major contribution) 
constricts (minor contribution) constricts 
Liver 
Kidney 
GI tract                                   
motility                                                  
sphincters                                               
secretion 
glycogenolysis, gluconeogenesis        
renin secretion 
                                            
decreases                               
contract                                          
no effect 
no effect 
no effect 
                                          
increases                                
dilate                                 
increases 
Pancreas                               
glucagon secretion                    
insulin secretion  
Adrenal medulla 
                                                             
increases                             
decreases 
noradrenaline and adrenaline 
secretion 
                                                   
increases                                  
increases 
no effect 
Platelets aggregation no effect 
Eye mydriasis                                   
long-range focus 
miosis                                    
short-range focus 
Urinary system                     
detrusor muscle                       
urethral sphincter 
                                                 
dilates                                    
contracts 
                                            
contracts                                
dilates 
 
Reproductive system               
uterus                                  
 
                                                   
contracts (pregnant), dilates (non-
pregnant)                           
                                                         
no effect 
 
 
Sweat gland secretion no effect 
Adipose tissue lipolysis no effect 
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Orthostatic test 
The posture change from lying to upright is known as the orthostatic test. The heart rate accelerates 
and blood pressure decreases after a change to a standing position. Blood pressure and heart rate 
differences between lying and upright postures in the orthostatic test relate to blood norepinephrine 
levels, and the orthostatic test has been used in non-invasive evaluation of the SNS (Ewing et al. 
1985). 
 
Baroreflex sensitivity 
Baroreflex sensitivity (BRS) means the effect of a change in blood pressure on the ensuing heart 
period. An increase in blood pressure is followed by increased heart beat duration and the steepness 
of the linear correlation between changes of systolic pressure and heart beat duration (ms/mmHg) 
gives an indication of BRS (Smyth et al. 1969). For assessing BRS, measurement of ECG, blood 
pressure, and optionally respiration, are analyzed by using various computerized methods. BRS 
reflects both PNS and SNS activity, and the information concerning the SNS has not been shown to 
be consistent (Karemaker 2002).  
 
Hand grip  
Static handgrip brings about marked increases in heart rate, arterial pressure, and muscle 
sympathetic nerve activity (Mark et al. 1985, Khurana and Setty 1996). Static handgrip is 
performed with the dominant hand, usually at 30% of maximal voluntary contraction, for 5 minutes. 
Changes in heart rate and blood pressure are monitored (Khurana and Setty 1996).  
 
NA spillover 
Plasma NA concentrations depend on sympathetic tone-induced NA secretion as well as removal 
(clearance) of the neurotransmitter from plasma. ‘Net’ NA secretion can be studied by measuring 
the appearance of radio-labelled NA into specific organs during intravenous infusion. Using NA 
plasma kinetic methodology, total body noradrenaline spillover to plasma can also be calculated 
(Esler et al. 1979). This dynamic process of NA release and removal has been shown to quantify 
sympathetic nervous activity better than steady-state plasma NA measurement alone (Esler et al. 
1979, Esler et al. 1988). Use of radioactive tracers, invasiveness of the method and need for special 
laboratory circumstances limits the use of NA spillover in clinical settings. During pregnancy, use 
of this method is contraindicated.  
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Muscle sympathetic nervous activity 
 Investigation of muscle sympathetic nerve activity (MSNA), assessed by microneurography, 
represents the only method available for direct recording of sympathetic nerve activity. Thin 
electrodes (10 μm) are inserted into a single nerve fibre of a skeletal (usually peroneal) muscle to 
record muscle sympathetic nerve impulses. Assessment of MSNA is an on-line dynamic method 
highly reproducible in healthy subjects (Vallbo et al. 1979). However, it is invasive and its use is 
restricted to the special laboratory environment. 
 
Heart rate variability  
Heart rate and rhythm are largely under the control of the ANS (Jalife et al. 1983). They are 
considered to result from sympatho-vagal interaction on the sinus node and to represent cardiac 
autonomic regulation (Ewing et al. 1984). Within the ANS, various regulatory systems associated 
with respiration, vasomotor control, baroreceptor reflexes and thermoregulation affect heart rate 
variability (HRV) (Malliani et al. 1991). 
 
Heart rate variability reflects fluctuations in the duration of consecutive R-R intervals (intervals 
between adjacent QRS complexes resulting in sinus node depolarization). It is influenced by 
respiration and it can be represented by the ratio of the duration of the longest heart beat in 
expiration divided by the duration of the shortest heart beat in inspiration, or the difference between 
respective heart beat durations. As analysis of HRV is based on mathematical models, it is 
relatively easily accomplished by using modern technology. In HRV analysis, the original ECG 
signal is converted from analogue to digital in a microcomputer. Before analyzing, the original ECG 
data must be edited by visual inspection and processing of artifacts and ectopic beats, which can 
markedly interfere with the analysis. The time intervals between consecutive peaks of the R waves 
form a tachogram (Figure 3).  
 
HRV can be analyzed as a function of time (time domain) and/or according to the distribution of 
variance during recording (frequency domain). In the time domain measures, the standard deviation 
of R-R intervals (SDNN) reflects the overall HRV in the period of recording. SDNN varies 
depending on the length of the recording period and therefore only recordings of same duration are 
appropriate for comparison (Task Force of the European Society of Cardiology and the North 
American Society of Pacing and Electrophysiology 1996). Other commonly used time domain 
measures include estimated changes in the long-term or short-term components of HRV. In 
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Figure 3. Heart rate variability tachogram and frequency domain indices. 
 
 
 
 
 
 
frequency domain analysis, also called power spectral density analysis, HRV is described as the 
sum of elementary oscillatory components defined by their frequency and amplitude (Figure 3) 
(Akselrod et al. 1981). Various algorithms can be used to assess the number, frequency and 
amplitude of the oscillatory components. Fast Fourier Transform (FFT, non-parametric) or 
autoregressive (parametric) approaches are most commonly used.  
 
Four major frequency bands are distinguished in a power spectrum from healthy subjects: high 
frequency (HF, 0.15–0.4 Hz), low frequency (LF, 0.04–0.15 Hz), very low frequency (VLF, 0.003–
0.04 Hz) and ultra-low frequency (ULF, <0.003 Hz) (Task Force of the European Society of 
Cardiology and the North American Society of Pacing and Electrophysiology 1996). The 
periodicities of fluctuation detected by these components are 2.5–7 s, 7–25 s, 25 s–6 min and >6 
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min, respectively. The powers of individual frequency components are represented by the areas 
under the proportion of the curve related to each component, and expressed both in absolute units 
(ms²) and normalized units (nu). Normalization minimizes the effect of changes in total power on 
the values of the HF and LF components. Normalized units are obtained by dividing the power of 
the given component by the total variance from which the VLF and ULF components have been 
subtracted and then multiplying by 100 (Malliani et al. 1991). The HF and LF components account 
for only approximately 5% of the total power, leaving 95% to ULF and VLF power. The 
physiological correlates of ULF and VLF are largely unknown.  
HRV represents mainly the activity of the PNS and the impact of the SNS on HRV is not clear. 
Decreased HRV (a.k.a. SDNN) is agreed to represent increased sympathetic activation, which can 
result, however, from both parasympathetic withdrawal and/or increased sympathetic input 
(Akselrod et al. 1985, Pomeranz et al. 1985, Pagani et al. 1986, Taylor et al. 1998, Malliani et al. 
1991, Eckberg 1997).  
In clinical studies, changes of HRV related to specific pathologies have been convincingly 
demonstrated only in the time domain parameters. In addition, the practical use of (depressed) HRV 
is clearly shown only as a predictor of risk for MI recurrence and as an early warning sign of 
diabetic neuropathy (Task Force of the European Society of Cardiology and the North American 
Society of Pacing and Electrophysiology 1996).   
Clinical implications of autonomic dysfunction  
As the ANS regulates various vital mechanisms of the human body, disturbances in its function may 
lead to detrimental events. Autonomic imbalance has been suggested as the final common pathway 
to increased morbidity and mortality from a host of conditions and diseases (Thayer et al. 2010). 
Changes in HRV have been found to be significantly associated with all-cause mortality after 
controlling for other risk factors (Tsuji et al. 1996, Liao et al. 2002).   
 
Heart failure, unstable angina and acute MI are associated with striking sympathetic overactivity, 
and extreme sympathoexcitation predicts mortality in patients with these conditions (Kleiger et al. 
1987, Odemuyiwa et al. 1991). Low HRV is also associated with the pathophysiology of CVD, i.e.  
progression of atherosclerosis (Huikuri et al. 1999), evolution of myocardial infarction (Tsuji et al. 
1996) and onset of arterial hypertension (Singh et al. 1998). In addition, increased SNS activity is 
associated with co-morbidities of CVD, such as essential hypertension (Fagard et al. 2001, Lucini et 
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al. 2002), obesity (Scherrer et al. 1994, Grassi et al. 1995, Sztajzel et al. 2009) and obstructive sleep 
apnoea (Narkiewitz et al 1998). The association between depressive disorders and sympathetic 
overactivity was demonstrated decades ago (Esler et al. 1982), but only recently brought up in 
relation to increased coronary heart disease risk in such patients (Esler 2009).   
 
Cardiovascular autonomic neuropathy is a general complication of diabetes characterized by 
widespread neuronal degeneration of small nerve fibres of both the sympathetic and 
parasympathetic tracts (Töyry et al. 1996, Duby et al. 2004). It is a key cause of morbidity and 
mortality in diabetes. The disease process may begin early in the course of diabetes but remain 
asymptomatic until later stages.  HRV analysis have been proven to be useful in detecting diabetes-
associated neuropathy, thus allowing risk stratification and earlier planning of subsequent 
management (Smith 1982, Ewing et al. 1991, Malpas and Maling 1990, Bellavere et al. 1992, 
Cacciatori et al. 1997, Schonauer et al. 2008).   
 
Inhibition of SNS activity is an effective means of lowering blood pressure. Peripheral α- and β-AR 
blocking agents belong to the conventional drugs in treatment of hypertension. In contrast to 
peripherally acting agents, central sympatholytic agents have the advantage of preserving normal 
physiological activation of the SNS during postural adjustments and exercise (Ernsberg et al. 1997, 
Greenwood et al. 2000). Such centrally acting SNS inhibiting agents include clonidine and newer 
antihypertensive drugs, imidazoline-1 receptor-specific agents, such as moxonidine and rilmenidine. 
Sympatholysis-mediated antihypertensive effects of these agents have been well documented. They 
reduce plasma catecholamine levels and muscle sympathetic activity as well as plasma renin in 
hypertension (Wenzel et al. 1998, Greenwood et al. 2000, Hausberg et al. 2010). There is also 
evidence of an effect of moxonidine on HRV (De Vito et al. 2002, Kaya et al. 2010). Besides their 
antihypertensive effects, improvement in glucose tolerance has been suggested in some, but not all 
studies (Ernsberg et al. 1997, Penicaud et al. 1998, Haenni and Lithell 1999, Masajtis-Zagajewska 
et al. 2010).  
 
 
Inflammation 
 
Inflammation represents a physiological protective process to maintain tissue homeostasis in 
response to harmful stimuli. Both exaggerated and insufficient inflammatory responses may lead to 
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a variety of diseases.  Inflammation may be caused by infection, but the inflammatory process may 
also be triggered by non-pathogens, such as damaged cells. Low-grade tissue inflammation refers to 
non-pathogen-induced inflammation with long-term low levels of inflammatory markers found 
either in the circulation or in tissues.    
 
Acute-phase proteins (APPs) are a class of proteins whose plasma concentrations increase or 
decrease in response to inflammation. In response to injury, local inflammatory cells (neutrophilic 
granulocytes and macrophages) secrete a number of cytokines, most notable of which are the 
interleukins (ILs) and TNFα. Liver hepatocytes, and to a lesser extent other cell types (monocytes, 
endothelial cells, adipocytes, fibroblasts) respond by producing a large number of APPs. APPs have 
a wide range of activities contributing to host defence, including inflammation-neutralizing and 
local tissue damage-minimizing actions as well as participation in tissue repair and regeneration.  
 
 
Inflammatory mediators 
 
Characteristics of the inflammatory mediators assessed in this study are presented in Table 2.  
 
 
Adiponectin 
Adiponectin, synthesized almost exclusively by adipocytes, is present in the blood at high levels 
compared with many other hormones (Ouchi et al. 2011). Adiponectin levels are decreased in obese 
compared with lean individuals in such a way that it is expressed at the highest levels by the 
functional adipocytes that are found in lean organisms, but its expression is down-regulated in the 
dysfunctional adipocytes that are associated with obesity (Ryo et al 2004).  
 
Plenty of data indicate that adiponectin is protective against the development of obesity-linked heart 
diseases, and it is considered as a molecular link between adipose and cardiovascular tissues (Ouchi 
et al 2011). The ability of adiponectin to suppress pro-inflammatory cytokine production, at least 
partly by modulation of macrophage function and phenotype, may be a key mechanism (Ouchi et al. 
2011). Negative correlations between adiponectin and many cytokines, such as CRP, IL-6 and 
TNFα, have been shown (Ouchi et al.2003). The results of several in vitro and in vivo studies have 
emphasized the ability of adiponectin to regulate glucose metabolism and insulin sensitivity in 
muscle and liver, and it has a modulatory function in vascular remodelling. Adiponectin has been 
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shown to promote vascular homeostasis and suppress the development of atherosclerosis (Ouchi et 
al 2003).  
 
Circulating concentrations of adiponectin seem to decrease slightly during pregnancy (Paradisi et al. 
2010) and GDM is associated with lower adiponectin concentrations than in normal pregnancy 
(Williams et al. 2003, Lain et al. 2008). Plasma levels of adiponectin are lower in patients with 
diabetes compared with non-diabetic controls, and in patients with CAD compared with age- and 
BMI-adjusted healthy individuals (Hotta et al. 2000, Ouchi et al. 1999). Adiponectin has shown to 
be an independent risk factor as regards CAD (Kumada et al. 2003). 
   
Alpha-1-acid glycoprotein 
The exact biological function of alpha-1-acid glycoprotein (AGP), also known as orosomucoid, is 
unknown. However, numerous activities of potential physiological significance have been 
described, including various immunomodulating effects and the ability to bind basic drugs and 
many other molecules, such as steroid hormones. In addition, AGP is considered as an acute-phase 
protein, since its serum concentrations increase several-fold during acute-phase reactions (Fournier 
et al. 2000). Elevated levels of AGP have been associated with cardiovascular diseases and type 2 
diabetes (Duncan et al. 2003, Engström et al. 2004). No data is available on the behaviour of AGP 
in GDM. 
 
C-reactive protein 
C-reactive protein (CRP) is a classical acute-phase protein produced mainly by the liver in response 
to pro-inflammatory cytokines including IL-6, IL-1 and TNFα. CRP is a mediator of immune 
responses against various pathogens and damaged cells of the host (Casas et al. 2008). However, in 
a recent critical review it was stated that “Despite many claims and assertions in the literature, 
neither the normal functions of human CRP nor its possible role in disease is known” (Casas et al. 
2008). The speed and dynamic range of CRP are remarkable, since plasma concentrations of CRP 
can rise by over 1000-fold in 24–48 h after a strong acute stimulus (e.g. sepsis, MI) and fall rapidly 
when the stimulus is removed (Casas et al. 2008).  
 
Modestly elevated baseline CRP levels have been associated with a long-term risk of coronary heart 
disease in general populations and use of CRP as part of a global coronary risk assessment strategy 
in adults without known cardiovascular disease  has been suggested (Pearson et al 2004, Danesh et 
29 
 
al. 2004). However, the pathogenic and clinical significance of associations between CRP and CVD 
is still controversial. In the context of other than acute-phase responses, the term ‘high-sensitivity’ 
CRP is used, and it refers to measurement of CRP using immunoassay methods with sufficient 
sensitivity to quantify CRP throughout its normal range (in contrast to measurement of acute phase 
responses).   
 
Circulating concentrations of CRP have been shown to be higher in healthy pregnant than in healthy 
non-pregnant individuals (Watts et al. 1991). In GDM, CRP levels have been shown to be elevated 
as early as in the first trimester in women who subsequently develop the condition. However, this 
association seems to be at least partly explained by BMI and weight gain during pregnancy (Leipold 
et al. 2005, Wolf et al. 2003) 
 
Serum Amyloid A 
Serum amyloid A (SAA) is a member of a family of apolipoproteins of which the most responsive 
to inflammatory stimuli, ‘acute-phase’ SAA, discussed here, is the archetypal vertebrate major 
acute-phase protein. It is induced from resting levels by more than 1000-fold during inflammation, 
implying an important (beneficial) role in host defence (Uhlar and Whitehead, 1999).  
 
Even though the primary physiological role of SAA remains obscure, many potential functions in 
humans have been proposed. These include modulation of the inflammatory response via both anti- 
and proinflammatory activities as well as involvement in cholesterol transport and metabolism 
(Uhlar and Whitehead, 1999, Urieli-Shoval et al. 2000).  
 
An increasing amount of data suggests that SAA, through these functions, may be a direct mediator 
in the development and progression of atherogenesis and atherothrombosis (Hua et al. 2009). SAA 
has been shown to be associated with an increased risk of cardiovascular events (Hua et al. 2009) as 
well as type 2 diabetes (Du et al. 2009).  No data is available on SAA in GDM.  
 
Sex hormone-binding globulin 
Sex Hormone-Binding Globulin (SHBG) is a multifunctional protein that modulates androgen and 
oestrogen actions in humans in two ways. By binding to plasma estradiol and testosterone, SHBG 
regulates the availability of sex hormones to responsive tissues. Secondly, sex hormone-bound 
SHBG may directly mediate cell-surface signalling and the biological actions of sex hormones 
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(Nakhla et al. 2009). Hyperoestrogenic states, such as pregnancy, are associated with high levels of 
SHBG whereas hyperandrogenism results into low levels of circulating SHBG.  
?
Clinical studies have revealed associations between low circulating levels of SHBG and many risk 
factors of CVD (Sutton-Tyrrell et al. 2005), and levels of sex hormones, both free and bound 
fractions, show associations with the risk of T2D (Ding et al. 2006,  Ding et al. 2007). In GDM and 
in women who develop GDM later in pregnancy, relatively low levels of SHBG have been shown 
as early as in the first trimester of pregnancy (Batrha et al. 2000, Nanda et al. 2011) 
 
 
Tumour necrosis factor α 
Tumour necrosis factor α (TNFα), also known as cachectin or simply TNF, was first identified as a 
factor causing fever and wasting. It was found to be product of lymphocytes and macrophages and 
cause lysis of certain types of cells, especially tumour cells (Beutler and Cerami 1986). By way of 
genetic studies it became evident that it is one product of a gene superfamily associated with host 
defence, inflammation, apoptosis, autoimmunity and organogenesis (Locksley et al. 2001).  
 
Most organs of the body appear to be affected by TNFα and it is produced by several types of cells, 
but especially by macrophages. TNFα has a variety of functions, including growth-stimulating 
properties and growth-inhibitory processes, beneficial immune responses to bacterial and certain 
fungal, viral, and parasitic invasions, as well as a role in local inflammatory immune responses 
(Locksley et al. 2001). 
 
Experimental data suggests that TNFα is involved in the pathogenesis of atherosclerosis by 
impairing endothelial function and endothelium–blood cell interaction. In addition, TNFα has been 
shown to impair insulin signalling (Kleinbongard et al. 2010). Increased plasma TNFα has been 
shown to predict a risk of cardiovascular diseases (Libby et al. 2002). In gene studies, TNFα-
promoting polymorphisms have been associated with type 2 diabetes as well as with conversion of 
glucose intolerance to type 2 diabetes (Heijmans et al. 2002, Kubaszek 2004).   
 
Circulating levels of TNFα have been found to increase during normal pregnancy, to correlate 
inversely with insulin secretion and to be associated independently with insulin sensitivity (Kirwan 
et al. 2002, McLachlan et al. 2006). In GDM, levels of TNFα have been found to be higher than in 
normal pregnancy (McLachlan et al. 2006).  
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Inflammation and atherosclerosis 
 
In the pathogenesis of atherosclerosis, inflammation plays a fundamental role at all stages from 
inception and development to the ultimate endpoint, thrombotic complication (Libby 2002, Abela 
2010). Elevated levels of several inflammatory mediators among patients with CVDs, as well as 
apparently healthy men and women, have proven to predict future adverse vascular events and 
deaths. Such mediators include CRP, IL-6, TNFα, fibrinogen and SAA (Haverkate et al. 1997, Toss 
et al. 1997, Harris et al. 1999, Ridker et al. 2000, Danesh et al. 2000, Libby 2002, Danesh et al. 
2005).  
 
Inflammation also links diabetes to atherosclerosis. Hyperglycaemia associated with diabetes can 
lead to glycation of various macromolecules, which augment the production of proinflammatory 
cytokines and promote other inflammatory pathways in vascular endothelial cells (Schmidt et al. 
1999). Circulating concentrations of CRP and IL-6 have been shown to predict development of T2D 
even among individuals with no current evidence of insulin resistance (Pradhan et al. 2001). 
 
Inflammation and the sympathetic nervous system 
 
There is increasing evidence that the immune system and the CNS interact, via autonomic 
pathways, continuously modulating each other (Elenkov et al. 2000, Tracey 2002). Sympathetic 
nerve terminals innervate both the primary and secondary lymphoid organs, which release NA, 
influencing lymphocyte traffic and proliferation, cytokine production and activity of lymphoid cells 
(Elenkov et al. 2000, Figure 1). Activation of the SNS exacerbates local as well as general immune 
and proinflammatory mediator responses (Flierl et al. 2007, Flierl et al. 2009, Johnson et al. 2005). 
In addition, the release of catecholamines from presynaptic sympathetic nerve terminals leads to 
localized vasoconstriction, preventing invading pathogens from becoming systemic (Elenkov et al. 
2000). On the other hand, the results of several studies indicate an inhibitory effect of the SNS on 
inflammatory responses by way of a decrease in the activity of natural killer cells and T cell 
immunity (Madden et al. 1989, van der Poll et al. 1994, Elenkov et al. 1996, Maestroni and 
Mazzola 2003). Cytokines can activate hypothalamic-pituitary release of glucocorticoids, which, in 
turn, suppress further cytokine synthesis. In addition, cells of the immune system can produce 
neuropeptides, such as acetylcholine (Tracey 2002).  
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Therapeutic agents acting in sympathetic α- and β-ARs have been shown to affect cytokine 
production. For example, α-AR antagonists have been shown to have inhibitory and α-AR agonists 
potentiating effects on TNFα production (Elenkov et al. 1996, Szelenyi et al. 2000).   
 
 
Adrenomedullin 
 
Human adrenomedullin (AM) is a ubiquitous hormone produced by a great number of different cell 
types in all tissues of the body, with the possible exception of the thyroid and thymus, and it has 
been shown to exhibit multifunctional biological activities in physiological as well as 
pathophysiological conditions (Hinson et al. 2000). Normal plasma concentrations of AM are in the 
range of 1 to 10 pmol/l (Hinson et al. 2000). Pregnancy is associated with a 5-fold increase in 
circulating AM concentrations at term and they revert to normal within 4 days after delivery 
(Wilson et al. 2004).  
 
Various biological actions have been demonstrated by way of peripheral and central administration 
of AM in animal and human studies. These are presented in Table 3. However, the only clinical 
situation in which concentrations of AM are shown to increase to levels that are required for 
activation of its receptors, is septic shock (Hinson et al. 2000). Therefore, the clinical relevance of 
AM outside life-threatening infections remains unclear.   
 
Concentrations of AM increase significantly in a number of disorders including cardiovascular 
diseases and diabetes (Hinson et al. 2000). Levels of AM are elevated in patients with T2D 
compared with healthy subjects and a stepwise increase occurs with advancing disease from 
impaired fasting glucose to T2D and diabetic nephropathy (Lim et al. 2007). Based on data so far, it 
appears that the observed changes in AM levels are compensatory to cardiovascular changes or 
injury, and that they represent a cardiovascular protective action (Hinson et al. 2000). However, 
fundamental information concerning the role of AM in humans is still lacking. Both animal and 
human studies have suggested an association between AM and the SNS (Taylor and Samson 2001, 
Krzeminski et al. 2006 and 2009, Troughton et al. 2001, Lainchbury et al.  1999).  
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Table 3.  Biological actions of adrenomedullin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coagulation 
 
Haemostasis is the body’s first line of defence against uncontrolled haemorrhage. Coagulation 
involves a complex set of protease reactions with roughly 30 different proteins (Colman et al. 
2006). The coagulation cascade, shown in Figure 4, is triggered when injury to a blood vessel 
allows blood to come into contact with tissue factor (TF)-bearing cells. Factor Xa (FXa) is the 
 Peripheral action Central action 
Cardiovascular system 
 
Vasodilatation  
 
Inotrophic and 
chronotrophic effects 
 
Endocrine system Inhibitory action on 
pancreatic islets 
Stimulation of renin 
release 
 
Inhibition of ACTH 
release 
 
Water and fluid balance 
 
Natriuresis and diuresis  
 
Inhibition of water 
drinking and salt 
appetite 
 
Autonomic nervous 
system 
Desensitization of 
baroreflex  
 
SNS stimulation 
Augmentation of 
baroreflex 
 
Immune system Antimicrobial    
properties  
Anti-inflammatory 
effect 
 
Coagulation  
(endothelial cells) 
Attenuation of TF 
expression  
Augmentation of 
synthesis and release of 
TFPI  
 
Induction of release of 
antithrombin  
 
Other Inhibition of gastric 
emptying 
Inhibition of 
bronchoconstriction 
 
Cell growth and 
differentiation 
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primary site of amplification in the process: one molecule of FXa catalyses the formation of 
approximately 1000 thrombin molecules (Mann et al. 2003). Activated haemostatic factor VIII 
(FVIII) plays a central role in the propagation of fibrin formation by activating FX in the presence 
of activated factor IX. The final step in the series of protease reactions leads to clot formation by 
transformation of soluble fibrinogen into insoluble fibrin strands forming a fibrin mesh, which ties 
cellular components of the clot (platelets and/or red blood cells). As soon as the clot has been 
formed, clot dissolution, fibrinolysis, starts to restore the structural integrity of the blood vessel 
wall. 
 
Factor VIII  
Factor VIII (FVIII) is an essential blood-clotting factor also known as anti-haemophilic factor. A 
genetic defect affecting FVIII results in haemophilia A, recessive X-linked coagulation disorder  
(Antonarakis 1995).  FVIII is synthesized by vascular, glomerular and tubular endothelium, and by 
the liver. In the blood, it is mainly bound to vWF to form a stable complex. Upon activation by 
thrombin, it dissociates from the complex to interact with Factor IXa in the coagulation cascade. No 
longer protected by vWF, activated FVIII is proteolytically inactivated and quickly cleared from the 
blood stream (Lenting et al. 1998).  
 
Elevated plasma levels of FVIII have been associated with an increased risk of venous thrombosis 
and pulmonary embolism (Kyrle et al. 2000). During normal pregnancy, FVIII levels seem to 
increase progressively by approximately 30%, beginning from the second trimester until the first 3 
days after delivery (Sanchez-Luceros et al. 2003). The risk of FVIII has been assessed only in one 
study. Scholtes and co-workers found an increased FVIII antigen/activity ratio in GDM, but only 
after 32 weeks of pregnancy (Choltes et al. 1983). 
 
Von Willebrand Factor 
Von Willebrand factor (vWF) is a blood glycoprotein essential for normal haemostasis, and 
deficiency of vWF causes von Willebrand disease, the most common inherited bleeding disorder. 
VWF mediates the adhesion of platelets to sites of vascular damage by binding to both platelets and 
exposed connective tissue. As mentioned above, vWF is also required for normal factor VIII 
survival in the circulation (Sadler et al. 1998).  
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Figure 4 Coagulation cascade 
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Von Willebrand factor has been demonstrated to be significantly predictive as regards adverse 
cardiac events in patients with pre-existing vascular disease, although this association is minor in 
the general population (Spiel et al. 2008). During normal pregnancy, levels of vWF have been 
shown to increase by approximately one third from the first trimester to puerperium, returning to 
non-pregnant levels within 2–3 weeks after delivery (Sanchez-Luceros et al. 2003). No data is 
available on vWF in GDM. 
 
Coagulation and atherosclerosis 
 
The ultimate endpoint in clinical vascular events is formation of a clot in a tapered vessel. The 
initiation of coagulation is triggered by TF, and platelet activation plays an important role. Elevated 
TF expression has been shown in all stages of atherosclerotic lesions, whereas a very low basal 
level in normal vessels is maintained (Wilcox et al. 1989, Steffel et al. 2006, Gertow et al. 2009). 
Platelet hyper-reactivity, high concentrations of many platelet-derived molecules, in particular 
FVIII, vWF antigen, and fibrinogen, as well as impaired fibrinolysis have been shown to be 
associated with and to predict atherothrombotic and venous thrombotic events (Peters et al. 1989, 
Cortellaro et al. 1992, Meade et al. 1993, Koster et al. 1995, Toss et al. 1997, Cushman et al. 1999, 
Smith et al. 2005). In addition to direct effects on the endothelium, platelets act as a ‘bridge’ for 
other cells within the vascular system, including leukocytes (Franks et al. 2010), thus providing a 
link between the coagulation and inflammatory systems. Specific interactions have been shown 
between the SNS and TF, macrophages (Libby and Simon 2001) and SAA (Zhao et al. 2007) 
(Figure 1).  
 
Coagulation and the sympathetic nervous system 
 
Dose-dependent stimulation of FVIII activity, vWF antigen, tissue plasminogen activator and 
platelets has been shown to occur shortly after an increase in the levels of circulating adrenaline. 
However, these responses are lacking or much weaker with NA (von Känel and Dimsdale 2000). 
The precise mechanisms underlying haemostatic changes in connection with sympathetic activation 
remain unclear. In healthy individuals, simultaneous activation of the coagulation and fibrinolysis 
systems by the SNS may be harmless, since the haemostatic balance is maintained within 
thrombosis and haemorrhage. However, in patients with impaired endothelial function, 
procoagulant responses appear to outweigh endothelial thromboprotective mechanisms (von Känel 
et al. 2001). Special attention has been paid to the early morning surge in catecholamine levels as a 
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result of circadian variation, possible sleep apnoea and postural change with getting up in relation to 
increased morning frequencies of thrombotic vascular events (von Känel and Dimsdale 2000, 
Masoud et al. 2008). 
 
 
Physiological alterations in pregnancy 
 
Pregnancy is associated with remarkable physiological alterations to ensure the survival and growth 
of the offspring. These changes, which are largely secondary to the effects of progesterone and 
oestrogen, begin after fertilization and are progressive. In the first 12 weeks of pregnancy, 
progesterone and oestrogen are produced predominately by the ovary and thereafter by the placenta 
(Ciliberto and Marx 1998). Maternal hormonal changes result in adjustments in physiology, 
especially in the cardiovascular, haemodynamic, haematological and metabolic systems, and lead to 
hypervolaemic, insulin resistant, thrombophilic and immunotolerant states. Thus, pregnancy can be 
regarded as a time period of general physiological stress in a woman’s life (Williams 2003, Kaaja 
and Greer 2005).  Physiological alterations in pregnancy are summarized in Table 3. 
 
Haemodynamic changes 
 
A number of mechanisms have been postulated for hypervolaemia of pregnancy. Oestrogen 
increases renin levels and causes sodium retention thereby increasing total body water. In addition, 
other hormones with increased concentrations during pregnancy, such as prolactin, placental 
lactogen, prostaglandins and growth hormone, may contribute to fluid retention (Ciliberto and Marx 
1998, Gallery 1998).  Plasma volume increases by 40–50%, and as this increase is relatively greater 
than the increase in red cell mass, maternal haemoglobin concentrations fall (Bernstein et al. 2001). 
The increased circulating volume offers protection for the mother and foetus from the effects of 
haemorrhage at delivery. 
 
Peripheral vascular resistance is reduced by 20% by oestrogen- and progesterone-mediated 
relaxation of vascular smooth muscle. This drop in systemic vascular resistance is a major maternal 
physiological adjustment to pregnancy beginning in early pregnancy, reaching a maximum in mid-
pregnancy, followed by a slow rise until term (Silversides and Colman 1998). The rise in cardiac 
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Table 4. .Physiological alterations in pregnancy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
output is facilitated by anatomical changes, namely left ventricular hypertrophy and dilatation 
(Silversides and Colman 1998). Renal vasodilatation and increase in glomerular filtration rate due 
to enhanced renal plasma flow result in increases in urea, creatinine and urate clearance. Plasma 
concentrations of these renal parameters are thus lower in pregnant than in non-pregnant women 
(Jeyabalan et al. 2003, Conrad et al. 2007).  
 
 
 
 
Haemodynamic changes Increased blood volume  
Increased heart rate 
Increased cardiac output 
Vasodilatation 
Decreased blood pressure 
 
Metabolic changes 
      
     lipids 
 
 
     
      
     glucose and insulin 
 
 
 
Body fat accumulation (early pregnancy) 
Catabolism (late pregnancy) 
Increased triglycerides, fatty acids, 
cholesterol, lipoproteins and phospholipids 
 
Increased insulin secretion 
Decreased insulin sensitivity 
Increased hepatic glucose production 
Increased carbohydrate use 
 
Haemostasis Increased coagulation 
Decreased fibrinolytic activity 
 
Inflammatory system Activation of the innate immune system 
Shift from cell-mediated to humoral 
immunity 
 
Sympathetic nervous system Activation (3rd trimester) 
 
39 
 
Metabolic changes 
 
Lipids 
Changes in carbohydrate and lipid metabolism occur during pregnancy to ensure a continuous 
supply of nutrients to the growing foetus despite scanty or intermittent maternal food intake. During 
early pregnancy there is an increase in body fat accumulation (anabolic state), whereas late 
pregnancy is associated with accelerated breakdown of fat depots (catabolic state). This catabolism 
in late pregnancy coincides with the maximal foetal growth phase, when the mother needs to 
progressively increase the energy supply to the foetus (Herrera 2002). From the beginning of the 3rd 
trimester there are steady increases in triglycerides, fatty acids, cholesterol (total, HDL and LDL), 
lipoproteins and phospholipids. High oestrogen concentrations and insulin resistance are thought to 
be responsible for these changes (Butte 2000).   
 
Insulin sensitivity and glucose homeostasis 
Insulin is essential in the utilization of blood glucose by binding to specific receptors on the surface 
of cells which display insulin-mediated glucose uptake. Tissue responsiveness to insulin, meaning 
how successfully the receptor operates to permit glucose clearance, is termed insulin sensitivity. 
Sensitivity to insulin varies approximately three-fold in non-pregnant lean subjects with normal 
glucose tolerance (Davidson 1995). Abnormally low insulin sensitivity is called insulin resistance.  
Insulin resistance is a common phenomenon, occurring in approximately 30% of the general 
population (Ioannou et al. 2007, Haffner and Miettinen 1997).  
 
During early pregnancy, glucose tolerance is normal or even slightly improved and peripheral 
insulin sensitivity is normal compared with the non-pregnant state. Women in early pregnancy are 
more sensitive to the blood glucose-lowering effect of exogenously administered insulin than they 
are later on in the second and third trimesters (Catalano et al. 1991, 1992, 1993). The cause of 
enhanced insulin secretion in early pregnancy is uncertain. 
 
During advancing pregnancy, insulin sensitivity decreases progressively, by as much as 50–70% in 
the 3rd trimester compared with healthy non-pregnant women (Ryan et al. 1985, Buchanan et al. 
1990, Catalano et al. 1991, 1992, 1993). Basal and both first and second phase postprandial insulin 
releases increase (Catalano et al. 1991, Lesser and Carpenter 1994).  
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In normal pregnancy, maintenance of normoglycaemia, despite insulin resistance, is achieved by 
way of enhanced insulin secretion by the pancreatic β-cells (Catalano et al. 1991). A likely 
contributing factor is hyperplasia of pancreatic islets (Van Assche et al. 1978).  
The physiological meaning and ultimate causes of pregnancy-induced insulin resistance are not 
known. However, pregnancy-induced factors, together with pro-inflammatory cytokines, like 
TNFα, are thought to play a role in development of insulin resistance (Radaelli et al. 2003). In 
addition, significant crosstalk exists between insulin and the SNS: muscle sympathetic activity is 
increased by insulin and acute activation of the SNS decreases insulin sensitivity (Rowe et al. 1981, 
Berne et al. 1992, Avogaro et al. 1996). 
Coagulation 
Normal pregnancy is associated with changes in all aspects of haemostasis, including increases in 
the concentrations of most clotting factors (e.g. factors I, V, VII, VIII, IX, X, XII) and adhesion 
protein vWF, decreasing concentrations of some of the natural anticoagulants (like protein S), and 
diminishing fibrinolytic activity (increased fibrinogen). In addition, platelets are activated during 
normal pregnancy. These changes lead to hypercoagulation, although anticoagulatory alterations 
also occur, such as increases in thrombomodulin and TFPI (Hellgren 2003, Brenner 2004).  
 
The most marked changes are seen around term and in the immediate post-partum period, and 
haemostasis is normalized approximately 4 weeks after delivery (Franchini 2006). Pregnancy-
induced haemostatic changes help in meeting the haemostatic challenge associated with delivery. At 
the same time they increase the risk of thromboembolism. This risk may be exacerbated by the 
concomitant presence of certain conditions, such as immobilisation or maternal thrombophilia. 
 
Inflammation 
 
Pregnancy represents a physiological state of activation of the innate immune system characterized 
by elevated circulating concentrations of many acute-phase inflammatory markers (von Versen-
Hoeynck et al. 2009, see also Table 2). Leucocytosis is present from the early stages of pregnancy 
and it increases towards the third trimester, and there is evidence for leukocyte activation (Belo et 
al. 2005, Smarson et al. 1996). Cytokines secreted from both immune and non-immune (e.g. 
decidual, chorionic) cells are thought to be involved (and even essential) in several aspects of 
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reproduction, including implantation, growth and development of trophoblasts, protection of the 
foetal allograft from maternal rejection, foetal fuel availability and parturition (Bowen et al. 2002, 
Saito 2000, Barbour et al. 2007).  
 
The placenta plays a marked role in synthesis and release of inflammatory proteins and virtually all 
known cytokines have been demonstrated to be expressed in the placenta (Bowen et al. 2002). In 
pregnant women, there is a shift from cell-mediated to humoral immunity; cytokines associated 
with humoral immunity and produced by Th2 cells (IL-4, IL-5, IL-6) predominate over those 
associated with cell-mediated immunity and produced by Th1 cells (IL-2, interferon γ, TNFα) 
(Challis et al. 2009).   
 
Obesity, particularly abdominal obesity, during pregnancy is associated with low-grade tissue 
inflammation, glucose intolerance and insulin resistance, with the result that pregnancy 
complications, such as gestational diabetes, are commoner in obese than non-obese women 
(Ramsay et al. 2002, Martin et al. 2009). Defects in the insulin signalling cascade have been 
described in pregnant obese women (Colomiere et al. 2009), but the biology of adipose tissue, and 
its links to insulin resistance, circulating inflammatory cytokines, and adverse pregnancy outcome 
need more investigation. 
 
Sympathetic nervous system  
 
Normal pregnancy is associated with increased SNS activity, especially in the 3rd trimester. This is 
demonstrated by assessment of circulating NA, HRV and muscle sympathetic activity recordings 
(Kaaja and Pöyhönen-Alho 2006). In the first trimester, vagal modulation overcomes sympathetic 
modulation, and the balance is shifted towards higher sympathetic and lower vagal modulation in 
the third trimester. This biphasic behaviour of the ANS during normal pregnancy may be affected 
by the balance between the haemodynamic changes and aorto-caval compression caused by the 
enlarging gravid uterus (Kuo et al. 2000).  
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Gestational diabetes 
 
Definition 
 
Gestational diabetes (GDM) is defined as glucose intolerance of variable severity with onset or first 
recognition during pregnancy (Metzger et al. 2007).  
 
 Pathophysiology 
 
Like all forms of hyperglycaemia, GDM is characterized by insufficient insulin production to meet 
insulin demands. Pancreatic β-cell dysfunction is pivotal but the causes are not fully defined. 
According to today´s knowledge, the underlying defects seem to be chronic rather than of acute 
onset: during pregnancy physiological insulin resistance unmasks an already existing β-cell defect 
which can still be detected years after pregnancy, even when glucose tolerance seems normal 
(Seghieri et al. 2007).  
 
Insulin resistance 
Two forms of insulin resistance exist in women who develop GDM: baseline insulin resistance 
presenting before pregnancy, and ‘superimposed’ physiological insulin resistance of late pregnancy. 
In GDM, the former is exacerbated by the latter. Even though women with GDM, as a group, are 
slightly more insulin-resistant than normal pregnant women (Metzger et al. 2007), they are far from 
homogeneous as regards the insulin resistance trait. The severity of insulin resistance in GDM 
varies widely between patients and is independent of degree of metabolic control (Natali et al. 
2006). These findings explain the great variability of results among studies concerning insulin 
resistance in GDM.   
 
Pancreatic β-cell function 
Women with GDM have lower insulin secretion for their degree of insulin resistance when 
compared with normal pregnant women (Di Gianni et al. 2003). A large body of evidence indicates 
that most (but not all) women with GDM have abnormal pancreatic β-cell function, especially as 
regards first-phase insulin secretion (Grill and Efendric 1987, Catalano et al. 1991, Miyakoshi et al. 
2010). The severity of β-cell dysfunction seems to correlate with the severity of glucose intolerance 
in women with GDM (Miyakoshi et al. 2010). Women with normal first-phase β-cell 
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responsiveness usually present with milder forms of GDM and are at relatively low risk of 
developing diabetes after pregnancy (Buchanan et al. 1990). A small minority of women with GDM 
appear to have β-cell dysfunction of autoimmune origin.  
 
Genetic factors 
Even though GDM clusters in families and common variants in several candidate genes have been 
demonstrated to increase the risk of GDM (Shaat and Groop 2007), the contribution of genetics is 
not well established. Increased prevalence of T2D in first-degree relatives of patients with GDM as 
well as a major role of ethnicity in the likelihood of developing GDM during pregnancy underline 
genetic predisposition (Martin et al. 1985, Anna et al. 2008).  
 
Role of the placenta and inflammation 
The placenta is a rich source of multiple substances, including steroids, peptides and lipid-derived 
molecules. During GDM, the placenta suffers remarkable structural and functional alterations. 
GDM has been reported to elicit major changes in the expression profile of placental genes for 
insulin signalling, lipid and glucose metabolism as well as inflammatory responses (Radaelli et al. 
2003, Colomiere et al. 2009, Lappas et al. 2005, Lappas et al. 2010). GDM is characterized by 
pronounced systemic inflammation compared with normal pregnancy (Bowen et al. 2002, Barbour 
et al. 2007, Challis et al. 2009, Volpe et al. 2007), and TNFα mRNA in skeletal muscle has been 
shown to be elevated in women with GDM even though circulating inflammation profiles have been 
similar to those in women with normoglycaemic pregnancies (Kim et al. 2008, Thomann et al. 
2008, Friedman et al. 2008). It has been hypothesized that low-grade tissue inflammation and 
insulin resistance, associated with excessive adiposity and pancreatic β-cell dysfunction, could 
favour the development of GDM, leading to type 2 diabetes and cardiovascular diseases later in life 
(Volpe et al. 2007).  
 
Modifiable factors 
Modifiable factors associated with the risk of GDM include physical activity and 
overweight/obesity. Although the effect of physical activity on prevention of T2D is clear, only a 
few studies have been conducted concerning GDM. However, these studies have demonstrated that 
physical activity before and during pregnancy is associated with a decreased risk of developing 
GDM (Tobias et al. 2011). Pre-pregnancy weight and GDM are closely linked, in that overweight 
and obese women have higher risks of developing GDM compared with women of normal weight 
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(Torloni et al. 2009). It has been calculated that a reduction in BMI of 1 kg/m² reduces the risk of 
GDM by 1% (Torloni et al. 2009).  Moreover, inverse correlation between socioeconomic status 
and GDM has been identified across various ethnic groups (Anna et al. 2008).   
 
Diagnosis and screening 
 
Both diagnosis and screening of GDM vary greatly worldwide. Recently, the International 
Association of Diabetes and Pregnancy Study Groups has formulated guidelines for screening and 
diagnosis of diabetes in pregnancy. Key components of the recommendations include screening of 
high-risk women at the first encounter for pre-gestational diabetes, universal screening at 24–28 
weeks' gestation, and use of the 75-g oral glucose tolerance test (Leary et al. 2010). Other widely 
used screening methods are risk-based screening and the 50-g glucose challenge test followed by 
the 100-g oral glucose tolerance test. In Finland, national guidelines for screening and diagnosis of 
GDM were recently introduced (Finnish Current Care Guidelines, 2008) and are schematically 
presented in Figure 5.  
 
Epidemiology 
 
The incidence of GDM varies among populations with recent prevalence estimates ranging from 
less than 2% in Sweden, to 22% in Sardinia (Hunt and Schuller 2007). In Finland, GDM was 
diagnosed in 2006 in 8.5% and in 2009 in 9.2% of parturients (STAKES birth register). Recent 
reports from the U.S., Canada, Australia and Europe provide evidence for an increasing prevalence 
of GDM (Cheung and Byth 2003, ACOG Practice Bulletin 2004, Dabelea et al. 2005, Hunt and 
Schuller 2007, Anna et al. 2009, Davenport et al. 2010). Even though these reports suggest an 
epidemic of GDM, estimates of global trends in incidence are made difficult by wide variability of 
glucose tolerance testing (glucose load, number and timing of tests, glycaemic thresholds). The 
increasing prevalence of obesity, particularly in youth, has been proposed as one of the causal 
factors for the apparent increase in GDM. Another noticeable factor is the survival of female infants 
whose birth weights are at the extremes of normal weights. The altered insulin action and insulin 
secretory capacity of these individuals may predispose them to development of GDM later in life.   
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Figure 5. Screening and diagnosis of gestational diabetes in Finland, Current 
                       Care Guideline. (www.kaypahoito.fi) 
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history of T2D 
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- no previous GDM     
- no previous infant         
> 4.5 kg                          
- BMI <25 
Other pregnant            
women 
Suspicion of GDM e.g. 
glucosuria 
2 h 75 g OGTT at 
the time of suspicion 
                   2-h 75-g OGTT at 24–28 weeks   
NORMAL 
 NORMAL Plasma glucose   
(mmol/l)                  
fasting  ≥ 5.3                 
1h         ≥ 10.0              
2h         ≥ 8.6   
                      NO GDM                          GDM 
No routine screening 
for GDM  
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Long-term health concerns 
 
Type 2 diabetes 
Over the long term, insulin secretion may deteriorate in relation to chronic insulin resistance present 
in women with GDM, eventually leading to T2D. Two large meta-analyses on the development of 
T2D following GDM report a risk ratio of 7.43 and prevalence of up to 70% (Bellamy et al. 2009, 
Kim et al. 2002). Progression increases steeply within the first five years, reaching a plateau soon 
thereafter (Kim et al. 2002). Once diagnosed with GDM, women appear to progress to T2D mostly 
regardless of ethnicity (Kim et al. 2002, Bellamy et al. 2009). Elevated fasting glucose levels 
observed during pregnancy strongly predict T2D; women with the highest glucose levels seem to 
have the highest risk (Kim et al. 2002). Other risk factors include high maternal age, high pre-
pregnancy BMI, early diagnosis of GDM and need for insulin therapy (Kim et al. 2002, Ogonowski 
and Miazgowski 2009).   
                                  
Cardiovascular diseases 
Individuals with T2D have a more than 20% risk of developing a new major coronary event within 
10 years following diagnosis (Haffner et al. 1998). In addition to T2D, women with pregnancy 
complicated by GDM more often develop hypertension, unfavourable lipid profiles and metabolic 
syndrome compared with those with a history of normoglycaemic pregnancy (Bentley-Lewis 2009). 
Surrogate measures of CVD, such as impaired endothelial function, cardiac autonomic dysfunction 
and elevated levels of CRP, have been shown to be associated with GDM compared with women 
with a normal pregnancy history (Bentley-Lewis 2009).  
 
Health consequences of GDM in the second generation 
Long-term health concerns affect not only women with GDM but also their offspring. Maternal 
glucose, but not insulin, crosses the placenta easily, resulting in intrauterine hyperglycaemia and 
compensatory foetal insulin secretion. This modification of the endocrine environment of the foetus 
has been suggested to change the programming of foetal metabolism, also affecting later childhood, 
and adulthood (Pedersen 1977, Radaelli et al. 2009, Luo et al. 2010). The risks of an overweight 
condition, metabolic syndrome, pre-diabetes and T2D are markedly increased in the offspring of 
women with GDM when compared with the background population, even in low-risk populations 
(Dabelea et al. 2000, Clausen et al. 2009, Vääräsmäki et al. 2009, Damm 2009).     
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Prevention  
Although GDM is a well-established risk factor of T2D, many women with GDM are either 
unaware or do not believe that they specifically are at risk of developing the disease (Bentley-Lewis 
et al. 2008). This might affect compliance with risk-reduction intervention. In order to increase 
awareness and acceptance of the personal risk of the development of T2D, public education 
campaigns as well as other easily available information are needed. Lifestyle modification studies 
have shown promising results in preventing or diminishing progression to T2D in several 
populations (Knowler et al. 2002, Tuomilehto et al. 2001, Pan et al. 1997), but no studies have 
specifically been conducted to assess healthy lifestyle intervention in women with GDM. In a recent 
meta-analysis, pre-pregnancy and early pregnancy physical activity were found to be protective 
against development of GDM, with odds ratios of 0.45 and 0.76, respectively (Tobias et al. 2011).  
 
Concerning prevention of T2D in women of fertile age, the benefit of breast-feeding is seldom 
considered, even though it seems to be protective, with a twofold reduction in the development of 
diabetes among both women with a history of GDM (Kjos et al. 1993) as well as women in the 
general population (Taylor et al. 2005).  
 
Pharmacological prevention of T2D after GDM is not currently recommended, but results from 
randomized placebo-controlled studies on glitazones (Buchanan et al. 2002, Xiang et al. 2006) as 
well as metformin (Knowler et al. 2002) in women with a history of GDM have shown marked risk 
reduction in progression to T2D. The incidence of diabetes has been shown to be reduced by 30% 
with metformin and by more than 50% with glitazones.   
 
. 
Sympathetic nervous system, insulin sensitivity and inflammation after 
menopause 
 
The occurrence of CAD is different in women and men, as onset begins approximately 10 years 
later in women (Mosca et al. 2007). A major increase in the incidence of CVD in women coincides 
with menopause, suggesting a role of oestrogen deficiency in this change. Studies on oestrogen 
therapy have also supported beneficial effects of hormonal therapy on insulin action and glucose 
tolerance (Szmuilowicz et al. 2009), but this hypothesis still remains to be proven and the possible 
underlying mechanisms investigated.  
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 Sympathetic nervous system  
 
Hormonal changes along a woman´s life span are associated with complex fluctuations in 
cardiovascular regulatory mechanisms, including the SNS. The first hormonal ‘storm’, puberty, is 
associated with variations in catecholamines (Weise et al. 2002). From menarche onwards, SNS 
activity correlates with plasma oestrogen levels, sympathetic control being higher during the luteal 
phase (high hormonal state) compared with the early follicular phase of a menstrual cycle 
(Hirshoren et al. 2002). Ageing has been shown to increase muscle sympathetic activity (Fagius and 
Wallin 1993) and the increase is more marked in women than in men, especially during menopause 
(Narkiewicz et al. 2005, Hart et al. 2009). Because the incidence of CVD in women increases 
markedly after the menopause, getting closer to that of men, these findings have led to the 
hypothesis that the SNS may play a role in the development of CVD in women after menopause. 
This view has also been supported by some work in humans suggesting that oestrogen decreases 
sympathetically mediated responses (Sudhir et al. 1997, Vongpatanasin et al. 2001, Kaaja and 
Pöyhönen-Alho 2006). However, these results are not conclusive (Niskanen et al. 2002). Thus, 
ageing of the homeostatic mechanisms involved in cardiovascular regulation, including the SNS, 
may be independent of sex, and sex steroid effects of endogenous and exogenous oestrogen may be 
mediated by different mechanisms (Narkiewicz et al. 2005, Lavi et al. 2007).    
 
Insulin resistance  
 
According to the current literature it is not unequivocal whether or not menopause is associated 
with increased insulin resistance. In a mouse model, gradual ovarian failure is associated with 
increasing insulin resistance (Romero-Aleshire et al. 2009), but studies in humans show conflicting 
results (Kaaja and Pöyhönen-Alho 2006, Lejskova et al. 2010, An et al. 2009). It is estimated that 
middle-aged women gain approximately 0.5 kg/year owing to an increase in abdominal obesity 
(Crawford et al. 2000, Toth et al. 2000) and at the same time muscle mass is reduced (Poehlman et 
al. 1993). In addition, postmenopausal years are associated with reduced energy expenditure 
(Poehlman et al. 1995). Menopause per se may thus not strictly be related to a decrease in insulin 
sensitivity, but be associated with unfavourable changes in body composition, especially an increase 
in central body fat (Denino et al. 2001, Manco et al. 2006, Aasen et al. 2009).    
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Inflammation  
 
It is well established that menopause coincides with changes in levels of systemic markers of 
inflammation as well as the incidence and progression of specific inflammatory conditions, such as 
coronary heart disease, asthma and inflammatory bowel disease (Gameiro et al. 2010, Gilliver 
2010). These changes can be partly explained by an increase in intra-abdominal fat after menopause 
(Lee et al. 2009), but abrupt cessation of ovarian oestrogen biosynthesis per se seems to play a role.?
Oestrogen is mainly considered to be an antioxidant, anti-inflammatory agent, via mechanisms that 
are not fully elucidated. At the cellular level, oestrogen influences chemotaxis, activation and 
secretion of inflammatory cytokines and adhesive interactions between inflammatory cells and the 
endothelium (Gilliver 2010). However, clinical studies have failed to show conclusive anti-
inflammatory effects of oestrogen (Gilliver 2010, Gameiro et al. 2010).  On the contrary, long-term 
oral (but not transdermal) use of hormonal therapy has been shown to increase plasma CRP levels 
(Shifren et al. 2008, Lowe et al. 2001, Zegura et al. 2003 and 2006).  
 
Postmenopausal hypertension 
Menopause is accompanied by an increase in BP independent of age, BMI and other confounding 
factors, including oestrogen therapy (Staessen et al. 1989, Zanchetti et al. 2005). Hypertension 
(followed by left ventricular hypertrophy) is the main risk factor contributing to the increase in 
cardiovascular morbidity and mortality in postmenopausal women, with a prevalence of around 
60% in women older than 65 years (Taddei 2009). The high prevalence of hypertension in older 
women is largely due to the progressive stiffening of the arterial structure which accompanies the 
ageing process in both sexes. However, the abrupt fall in circulating oestrogen concentrations might 
independently contribute to the rise in BP through a direct effect on the arterial wall and activation 
of the renin-angiotensin system (Vongpatanasin et al. 2001, Yanes et al. 2010). 
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AIMS OF THE STUDY 
 
Because the pathophysiology of GDM and mechanisms behind the transition of GDM to T2D are 
incompletely understood, we aimed to study 
 
1. Nocturnal SNS activity in pregnancy complicated by GDM compared with normal 
pregnancy  
 
2. Subclinical inflammatory cytokines, and associations of the SNS with these cytokines 
 
 
3. Coagulation, and associations of coagulation and fibrinolysis markers with the SNS 
 
4. Effect of central inhibition of the SNS on inflammatory cytokines  
 
 
SUBJECTS AND METHODS 
 
Subjects  
 
The subjects in the two studies in this thesis are presented in Table 5.  
 
Methods 
 
Publications I–III 
 
Treatment of GDM followed the clinical guidelines of Helsinki University Central Hospital. Dietary 
treatment, consisting of 1600–1800 kcal/day, was started immediately after the diagnosis of GDM. 
If fasting or 1-h postprandial plasma glucose levels exceeded 5.5 or 7.8 mmol/l, respectively,  
insulin treatment was initiated. Initially, NPH insulin in a single evening dose was used and, in 
cases of postprandial hyperglycaemia, short-acting insulin prior to meals was introduced.   
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Table 4.  Study subjects. 
 
 
 
*   previous diagnosis of hypertension, or diastolic BP values ≥90 mmHg and/or systolic values  
     ≥140 mmHg during the first trimester of pregnancy.  
** cessation of menstruation 1–5 years earlier, serum follicle-stimulating hormone ≥30 IU/l and a 
     menopause sign score ≥1 (each menopausal symptom – hot flashes, palpitations, insomnia,  
     irritability and depression – graded as 0=absent, 1= mild, 2= moderate, 3= severe). 
 
 
 
All study subjects spent one night in hospital and the same investigator (M.P-A.) performed all the 
clinical studies. To standardize menstrual cycle-dependent SNS activity, the NPCs were studied at 
mid-cycle, which was confirmed by way of menstrual history and vaginal ultrasonographic 
examination. For blood sampling a cannula was inserted into a cubical vein. Blood samples were 
drawn during the night at 24, 4 and 7 h to determine plasma NA, AM and insulin concentrations. 
 
 The coagulation variables examined included prothrombin time (PT), thrombin time (TT), 
activated partial thrombin time (APTT), fibrinogen D-dimer, FVIII activity (FVIII:C), vWF antigen 
Study group No. of 
subjects 
Inclusion criteria Exclusion criteria 
Publications I–III    
GDM 
  - normal BP 
  - hypertension* 
41 
23 
18 
at least one 75-g 2-h OGTT value 
abnormal:   
≥5.3 mmol/l (fasting state), ≥10.0 
mmol/l at 1 h and ≥8.6 mmol/l at  
2 h 
 
smoking 
clinical signs of infection  
 
medication affecting glucose 
metabolism,  
PCs 22 normal OGTT, normal BP, BMI 
>25kg/m² 
the sympathetic nervous system  
or 
NPCs 14 no history of pathological blood 
glucose values or hypertension, 
BMI >25kg/m² 
coagulation 
Publication IV    
Moxonidine 56 natural menopause**   
Atenolol 56 hypertension (mean of 3 sitting 
diastolic BP measurements  95–
114 mmHg),  BMI >25kg/m² 
use of any other medication 
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(vWF:Ag), ristocetin cofactor activity (vWF:RCo) and collagen binding activity (vWF:CB) as well 
as primary haemostasis (assessed via PFA-100®).  
 
The inflammatory cytokines studied were CRP, IL-6, insulin growth factor-1 (IGF-1), SAA, sex 
hormone-binding globulin (SHBG), alpha-1 glycoprotein (AGP) and cortisol. At the same time a 
fingertip blood sample was taken for blood glucose determination. The study participants were 
asked to sleep or to stay in bed in a lying position during the whole study period and to list all 
obligatory standing-up times. Supine blood pressure was measured twice, 5 minutes apart, in the 
morning before getting up. All study subjects underwent 2-channel overnight ECG recording for 
assessment of HRV. The HRV analyses were initiated at 23 h and continued until 8 h. We chose 
this night-time recording period rather than a full 24 hours in order to standardize, as far as possible, 
the study environment as recommended for clinical studies (Task Force of the European Society of 
Cardiology and the North American Society of Pacing and Electrophysiology 1996). 
 
The study was approved by The Ethics Committee of Gynaecology and Obstetrics of the hospital 
district of Helsinki and Uusimaa, and written informed consent was obtained from all participants.  
 
Blood sample analyses 
Blood was collected into specific tubes (NA and AM: cooled EDTA tubes; assays for coagulation 
parameters: cooled 109 mM (3.2%) trisodium citrate; assays for inflammation: cooled serum tubes), 
centrifuged immediately at 4 °C for 15 minutes at 3000 g and the separated plasma was frozen in 
aliquots at -80 °C until assayed. NA and AM samples were transported to New Zealand on dry ice 
and assays were carried out at Christchurch Hospital, New Zealand, in duplicate, and all samples 
from each individual were measured in a single assay (Mefford et al. 1981, Lewis et al. 1998).  
Coagulation and inflammation analyses were performed using commercially available kits at 
Biomedicum laboratory, Helsinki and the laboratory of Helsinki University Hospital (HUSLAB) 
according to the manufacturer’s instructions. The methods for blood sample analyses and the 
reference ranges are listed in Table 6.  
 
HRV analyses 
ECG tapes were initially visually analyzed to label the QRS complexes and classified with respect 
to normal or ventricular extrasystoles. Analysis of HRV was carried out with custom-made software  
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Table 6. Blood sample analyses 
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suitable for moving-time HRV analysis (Aalto University, Helsinki, Finland, 
heikki.vaananen@tkk.fi). The following two time-domain components of HRV were measured: 
 
SDNN, representing the standard deviation of the nightly sinus node cycle length, and the standard 
deviation of the average normal-to-normal intervals for each 5-min period, SDANN. Frequency-
domain analysis was performed using fast Fourier transformation. Before this the normal-to-normal 
time series was re-sampled with a boxcar window, convoluted with a Hanning window, and the 
linear trend was removed. The frequency-domain indices VLF, LF and HF as well as the LF to HF 
ratio were then calculated. In addition to absolute values, LF and HF data were transformed into 
normalized units (nu). Frequency domain indices were analyzed over the whole 9-h period and 
additionally over a one-hour period before each blood sampling.  
 
Publication IV 
 
This multicentre (10 centres) and multinational (Finland, Sweden, Lithuania) study design was a 
prospective and double-blind comparison of moxonidine and atenolol. After a 4-week placebo run-
in phase the patients were randomly assigned for 8 weeks to 0.3 mg moxonidine twice or 50 mg 
atenolol once daily. Matching placebo tablets were used in the atenolol group to achieve twice-daily 
administration. During the course of the study, including the 4-week run-in period, the patients were 
not to receive any other forms of antihypertensive medication, which were discontinued for 2 
weeks, and in the case of β-blockers, for 1 month prior to the run-in period. Compliance to the 
medication was regarded as sufficient if the subject took at least 85% of the scheduled medication. 
Blood samples for analysis of the inflammatory markers (CRP, TNFα, TNFα receptor II , IL-6 and 
adiponectin) were taken at the beginning of the study (after the run-in period) and after 8 weeks of 
medical treatment.  
 
All samples were analyzed in the same laboratory (Yhtyneet Laboratoriot, Helsinki, Finland). If the 
result of an inflammation marker test was lower or higher than the sensitivity of the test used, the 
result was expressed as the lowest or highest sensitivity detection value, correspondingly. The 
lowest detection rate used for TNFα was less than 0.06 pg/ml, and the highest rate for IL-6 more 
than 10 pg/ml and for adiponectin more than 25 000 pg/ml. Participants with CRP levels of > 10 
mg/l at baseline and/or after the follow-up period were excluded because of the risk of infection as a 
confounding factor.  
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Statistics 
 
Publications I–III 
 
 A sample size of 19 patients per group, in detecting a difference in plasma concentrations of NA of 
300 pmol/l (SD 320 ) between the groups, was calculated by using a two-sided t-test with =0.05 
and power=80%. The variables were initially analyzed by using repeated measurements analysis of 
variance (RMANOVA) for difference over time, group and group and time interactions. Variables 
measured only at baseline were analyzed by means of a simple analysis of variance (ANOVA) 
model. Paired or unpaired Mann–Whitney U-tests were used to compare groups and different time 
points as appropriate. Concerning CRP and SAA measurements, logarithmic transformations were 
carried out because of reasonably wide variability of single measurements of these variables and to 
achieve more reliable information on comparisons between the groups. Pearson’s (publication I) 
and Spearman's correlation coefficients (publications II and III) were calculated from the entire 
data. Linear regression analysis was performed to evaluate the effect of BMI on the measured 
variables. Analyses were carried out using SAS® software, version 8.2, SAS Institute Inc., Cary, 
NC, USA (publication I) and PASW® software, version 18.0 for Windows; SPSS Inc., Chicago, IL, 
USA (publications II and III).  
 
Publication IV  
 
Sample size estimation and power calculation were performed with a power of 80% to reject the 
null-hypothesis at a 5% level. The standard deviation of the target parameter, diastolic BP, is known 
from other studies to be 6.5 mmHg. Assuming a clinically relevant difference to be 4 mmHg, and 
using a one-sided t-test, a sample size of 57 patients per treatment group was required. The 
difference between treatment groups in distribution of change in inflammatory markers was 
analyzed using nonparametric analysis of covariance with baseline values as covariates. The study 
was accepted by the Ethics Committees of each participating centre.  
 
 
 
 
56 
 
RESULTS  
 
Characteristics of the study groups 
 
Publications I–III 
 
Four subjects were excluded from the analyses because of occasional smoking not apparent at the 
time of recruitment (2 women in the GDM group with hypertension and 1 with normal BP, and 1 
woman in the PC group). Baseline characteristics of the study groups are presented in Table 6.  The 
women in the GDM group appeared to be more obese when compared with PCs and NPCs but 
gained less weight during pregnancy, most probably as a result of dietary treatment. The NPCs had 
had fewer previous pregnancies than the other groups. Eight of the 38 GDM subjects (21%) needed 
insulin in addition to dietary treatment. No differences were found in baseline characteristics 
between diet-only and insulin-treated GDM subjects, with the exception of higher levels of blood 
glucose  in insulin-treated subjects at all time points (24 h, 5.7 vs. 4.9 mmol/l, p=0.0004; 4 h, 5.7 vs. 
4.9 mmol/l, p=0.0007 and 7 h, 5.7 vs. 4.8 mmol/l, p<0.0001). 
 
Five of the hypertensive GDM subjects used oral labetalol hydrochloride (combined α- and β-
blocking agent) as antihypertensive medication.  Because of the potential effect of this medication 
on SNS activity these patients were excluded from analyses of SNS (HRV, NA and their 
associations). For technical reasons (faulty Holter recorder), reliable HRV data were unavailable in 
27 subjects, leaving reliable HRV data from 47 women, 26 in the GDM group (18 with normal BP 
and 8 with hypertension), 12 in the PC group and 9 in the NPC group.  
 
Publication IV 
 
Nineteen women were excluded because of lack of data (time of menopause, diastolic BP, BMI at 
baseline) or a blood sample. Four participants in the atenolol and two in the moxonidine group were 
excluded because one or both CRP values exceeded 10 mg/l. Thus the final study population 
included 44 patients with atenolol and 43 with moxonidine treatment. The study groups were 
comparable according to their baseline characteristics (Table 7).  
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Table 7. Characteristics of the study groups, mean (SD) 
 
 
 
 
ap<0.05 GDM vs. PCs and NPCs 
bp<0.001 NPCs vs. GDM and PCs      
cp<0.05 PCs vs. GDM and NPCs    
 
GDM, gestational diabetes; PCs, pregnant controls; NPCs, non-pregnant controls; BMI, body mass index; BP, blood 
pressure 
 
 
 
 
 
 
 
 
 
 
 
 
Publications I–III 
 
GDM 
(n=41) 
PCs 
(n=22) 
NPCs 
(n=14) 
  
 Age (years) 
 
34.0 (5.6) 
 
29.5 (4.9) 
 
30.4 (6.9) 
BMI (kg/m²)   30.6 (6.0) a 26.9 (3.0) 26.5 (6.3) 
Parity   2.2 (1.4)   1.2 (0.9)     0.5 (0.4) b 
Weight gain during pregnancy 
(kg) 
  11.0 (6.3) a 16.3 (8.9)  
Duration of pregnancy at time of 
study (d) 
    211.8 (30.6)     216.0 (16.9)  
Systolic BP (mmHg)     119.7 (17.7)     113.3 (10.8)       113.4 (8.2) 
Diastolic BP (mmHg)       71.5 (10.7) 67.1 (7.1)         69.9 (9.5) 
Blood glucose at 24 h (mmol/l)   5.1 (0.6)   5.1 (0.6)     6.1 (0.7) b 
Blood glucose at 4 h   5.1 (0.6)   4.9 (0.4)           5.4 (0.5) 
Blood glucose at 7 h   5.0 (0.5)      4.6 (0.3) c           5.3 (0.6) 
Number of upright positions   2.0 (1.1)    1.5 (1.4)           1.2 (1.2) 
Breathing frequency/min       29 (6)        26 (8)       25 (5) 
 
Publication IV ATENOLOL 
(n=43) 
MOXONIDINE 
(n=44) 
   
Age (years) 53.4 (2.8) 53.4 (3.1) 
BMI  (kg/m²) 30.9 (4.0) 29.3 (4.0) 
Diastolic BP (mmHg)     101 (5)     102 (5) 
Systolic BP (mmHg)   160 (16)   160 (18) 
Fasting blood glucose (mmol/l)   5.5 (0.8)   5.5 (0.9) 
Fasting insulin (mU/) 11.9 (6.3) 11.6 (7.0) 
Insulin sensitivity (Matsuda index)   4.2 (2.1)   4.7 (2.8) 
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Sympathetic nervous system 
 
Noradrenaline 
 
Nocturnal changes of NA concentrations are shown in Figure 6. In both the GDM group and the 
PCs, mean NA levels increased significantly during the early morning hours from 4 to 7 h, with no 
difference between the groups. The change from 24 to 7 h was different in the GDM and NPC 
groups (p<0.001), and in the PC and NPC groups (p=0.008). The change from 4 h to 7 h was 
significantly different between PCs and NPCs (p=0.022) and nearly significant between women 
with GDM and the NPCs (p=0.067).  
 
 In a sub-analysis, no differences in NA levels were found within the GDM group between women 
with normal BP vs. hypertension. 
     
 
Figure 6.  Time-associated nocturnal changes of noradrenaline concentrations in the study 
                             groups. Mean±SD. 
 
 
 
*     GDM: change from 24 to 7, p=0.001 and change from 4 to 7, p<0.01 
**   PCs:  change from 4 to 7, p<0.01 
*** NPCs: change from 24 to 7, p<0.05 and change from 24 to 4, p<0.05 
* 
** 
*** 
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Heart rate variability 
 
Time- and frequency-domain analyses of HRV are presented in Figure 7. Both pregnant groups 
showed lower SDNN and SDANN values as well as lower LF values than the NPCs. The GDM 
group exhibited lower HF values than the NPCs. No differences existed in LF/HF between the 
groups. Although the GDM and PC groups did not differ in respect of 9-hour HRV, a difference in 
the change profiles of HFnu and LFnu was evident (Figure 8). HFnu and LFnu values as well as 
their ratios remained unchanged in the GDM vs. the PC and NPC groups.    
 
 
Figure 7.   Time- and frequency-domain indices of HRV 
 
 
 
* 
* 
p<0.01  
GDM vs. NPCs 
* 
*p<0.001 
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Figure 8.  Proportional differences in nocturnal biological variation in women diagnosed with  
                      gestational diabetes compared to women with normal pregnancy. 
 
 
  
 
                                               
  *p<0.05  
 
 
 
Inflammatory markers 
 
Conclusive results regarding inflammatory parameters are presented in Table 1 of the original 
publication II. CRP concentrations were higher during pregnancy compared with the non-pregnant 
state. Also, concentrations of IGF-1, SHBG and cortisol (except at 24 h) were higher in pregnant 
than in non-pregnant subjects. No differences were seen in levels of any of the studied variables 
between the GDM and PC groups. However, concentrations of CRP and SAA remained almost 
constant during the night in the GDM group, whereas variation was seen in normal pregnancy 
(Figure 8).  
 
The only correlation between NA and inflammatory cytokines was seen with SAA in the GDM 
group (r=0.43, p=0.016). No such correlation existed in PCs and NPCs. 
                BIOLOGICAL VARIATION IN NORMAL PREGNANCY 
 
* 
 
* 
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Changes in inflammatory markers in the study in which we compared 8-week use of atenolol or 
moxonidine in hypertensive overweight postmenopausal women are presented in Table 8. Levels of 
CRP and IL-6 did not differ between the groups. Concentrations of TNFα increased in the atenolol 
group but decreased in the moxonidine group and the difference was even greater as regards 
adiponectin, the concentrations of which decreased dramatically in the atenonol group but did not 
change in moxonidine treatment group. In regression analysis, only treatment group independently 
affected changes in levels of adiponectin and TNFα.  
 
 
                         Table 8.   Changes in inflammatory parameters from baseline to 8 weeks in 
                                   subjects using atenolol and moxonidine. Mean (SD). 
 
 
 
 
 
The effects of atenolol compared with those of moxonidine on BP and insulin sensitivity in the 
same study population have been published earlier (Kaaja et al. 2007). Mean BP decreased 
significantly during the 8-week period in both atenolol- (9.5 mmHg, p<0.001) and moxonidine-
treated patients (6.2 mmHg, p<0.001). In patients in whom blood pressure was reduced, insulin 
sensitivity improved in the moxonidine group (p=0.02), but not in the atenolol group. 
 
 
 
 
 
 
 
Parameter 
 
ATENOLOL 
n=44 
 
MOXONIDINE 
n=43 
 
p-value 
 
CRP (mg/l) 
 
0.7 (3.0) 
 
0.5 (6.3) 
 
ns 
TNFα (ng/l)            0.05 (0.1)           -0.03 (0.2) <0.001 
TNFα-RII (ng/l)          4.4 (233.6)        52.6 (370.6) ns 
IL-6 (ng/l)            0.19 (0.7)            0.03 (0.6) ns 
adiponectin (μg/l) -1733.3 (2754.7)      13.7 (1921.9) <0.0001 
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Insulin 
 
Nocturnal alterations in insulin levels are shown in Figure 9. Concentrations of insulin remained 
almost constant in the GDM group between the sampling times, whereas distinct variation (decrease 
towards morning) was evident in the PCs and NPCs. Insulin concentrations were higher in the 
GDM group than in the NPCs at 4 am and 7 am, whereas no statistical difference existed between 
PCs and NPCs.   
 
 
 
Figure 9.  Nocturnal variation of insulin concentrations. Mean±SD.  
 
 
 
 
* p<0.01 GDM vs. NPCs 
 
 
 
 
 
 
* 
* 
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Adrenomedullin 
 
Plasma concentrations of ADM were higher in pregnant than in non-pregnant women at all time 
points (p<0.001), as shown in Figure 10. No difference existed between the GDM group and PCs. 
 
 
 
 
 
Figure 10.  Nocturnal variation of adrenomedullin concentrations. Mean±SD. 
 
 
 
 
 
 
*p<0.001 GDM and PCs vs. NPCs 
 
 
 
 
 
 
 
 
  *   * *
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Haemostatic variables 
 
Coagulation and fibrinolysis 
 
Pregnancy was associated with changes in all aspects of haemostasis towards enhanced coagulation 
activity compared with the non-pregnant state (see publication III, Table 2). No differences existed 
in coagulation and fibrinolysis variables or in clotting times in the GDM and normal pregnancy 
groups, with the exception of FVIII:C, which was lower in the GDM group than in the PCs. The 
differences were statistically significant at 4 and 7 h, and approached significance at 24 h (p=0.07). 
In addition, the levels of all variables of vWF appeared to be lower in the GDM group than in the 
PCs, even though the differences were not statistically significant (Table 9).  
 
Thrombin time and APTT increased slightly in the GDM group from 4 to 7 h, but not in the other 
groups. A moderate correlation was found between NA concentrations and APTT (r=0.28, p=0.02). 
 
BMI had a modest effect on fibrinogen levels (r=0.12–0.13, p=0.006–0.009; linear regression), but 
no or only a minor effect on the other variables.   
 
Platelet function  
 
In platelet function studies, no differences existed between GDM and normal pregnancy. In 
pregnant vs. non-pregnant subjects, a shorter time in clot formation at midnight, i.e. increased 
platelet activity, was found, as measured by PFA-100. In non-pregnant women, the time needed 
for clot formation shortened markedly towards the morning, whereas no change was seen in 
pregnant women (Figure 11). In linear regression analysis, BMI explained only 1–5% of the clot 
formation times. 
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Table 9. Haemostatic changes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
ab
le
 9
. N
oc
tu
rn
al
 v
ar
ia
tio
n 
of
 F
ac
to
r 
V
II
I,
 v
on
 W
ill
eb
ra
nd
 F
ac
to
r,
 th
ro
m
bi
n 
tim
e 
an
d 
ac
ti
va
te
d 
pa
rt
ia
l t
hr
om
bo
pl
as
tin
 ti
m
e.
 M
ea
n 
(S
D
).
G
D
M
, g
es
ta
tio
na
l d
ia
be
te
s;
 P
C
s,
 p
re
gn
an
t c
on
tr
ol
s;
 N
PC
s,
 n
on
-p
re
gn
an
t c
on
tr
ol
s;
 F
V
II
I:
C
, f
ac
to
r 
V
II
I 
ac
tiv
it
y;
 v
W
F
, v
on
 W
ill
eb
ra
nd
 f
ac
to
r,
vW
F
:A
g,
 v
W
F 
an
ti
ge
n,
 v
W
F
:R
C
o,
  v
W
F 
ri
st
oc
et
in
 c
of
ac
to
r 
ac
tiv
ity
; 
vW
F
:C
B
, v
W
F 
 c
ol
la
ge
n-
bi
nd
in
g 
ac
ti
vi
ty
; n
s,
 n
on
-s
ig
ni
fi
ca
nt
S
am
p
li
ng
ti
m
e 
(a
t)
G
D
M
(n
=
38
)
P
C
s
(n
=
21
)
N
P
C
s
(n
=
14
)
p-
va
lu
e
G
D
M
 v
s.
 P
C
s
G
D
M
 v
s.
 N
PC
s
P
C
s 
vs
. N
PC
s
F
V
II
I:
C
0
12
6.
2 
(2
9.
8)
14
0.
7 
(2
5.
8)
78
.6
 (
26
.2
)
ns
<
0.
00
0
<
0.
00
0
(%
)
4
11
9.
9 
(2
4.
3)
14
3.
9 
(4
2.
7)
78
.4
 (
30
.5
)
<
0.
00
0
<
0.
00
0
<
0.
00
0
7
11
9.
5 
(3
2.
0)
14
0.
0 
(2
4.
3)
75
.9
 (
25
.9
)
0.
03
<
0.
00
0
<
0.
00
0
vW
F
:A
g
0
17
9.
0 
(7
5.
9)
19
3.
5 
(5
7.
6)
83
.1
(2
9.
0)
ns
<
0.
00
0
<
0.
00
0
(%
)
4
17
4.
7 
(7
3.
6)
18
9.
7 
(6
1.
1)
75
.5
 (
25
.2
)
ns
<
0.
00
0
<
00
00
7
17
9.
3 
(7
2.
0)
18
9.
2 
(5
8.
6)
75
.4
 (
21
.4
)
ns
<
0.
00
0
<
0.
00
0
vW
F
:R
C
o
0
18
3.
8 
(6
8,
2)
19
7.
4 
(7
4.
8)
85
.6
 (
35
.1
)
ns
<
0.
00
0
<
0.
00
0
(%
)
4
17
9.
6 
(6
7.
4)
19
7.
6 
(8
1.
1)
80
.6
 (
35
.7
)
ns
<
0.
00
0
<
0.
00
0
7
18
6.
4 
(6
6.
3)
19
9.
2 
(7
8.
5)
83
.9
 (
32
.2
)
ns
<
0.
00
0
<
0.
00
0
vW
F
:C
B
0
16
0.
3 
(7
6.
8)
17
1.
2 
(6
4.
2)
69
.1
 (
17
.4
)
ns
<
0.
00
0
<
0.
00
0
(%
)
4
14
8.
9 
(6
6.
6)
16
5.
8 
(6
2.
6)
72
.7
 (
25
.4
)
ns
<
0.
00
0
<
0.
00
0
7
14
8.
4 
(6
3.
3)
16
0.
8 
(6
5.
3)
68
.2
 (
22
.4
)
ns
<
0.
00
0
<
0.
00
0
T
hr
om
b
in
T
im
e
0
15
.5
 (
1.
7)
15
.0
 (
0.
7)
17
.8
 (
1.
8)
ns
<
0.
00
0
<
0.
00
0
(s
)
4
15
.5
 (
1.
2)
15
.1
 (
0.
6)
18
.1
 (
1.
5)
ns
<
0.
00
0
<
0.
00
0
7
17
.6
 (
13
.2
)
15
.1
 (
0.
8)
17
.7
 (
1.
5)
ns
ns
<
0.
00
0
A
P
T
T
0
25
.2
 (
2.
2)
25
.0
 (
1.
4)
27
.1
 (
1.
9)
ns
<
0.
00
1
<
0.
00
1
(s
)
4
25
.3
 (
1.
5)
24
.3
 (
1.
8)
27
.4
 (
2.
6)
0.
04
<
0.
00
0
<
0.
00
0
7
26
.1
 (
5.
4)
24
.6
 (
1.
5)
27
.5
 (
2.
1)
ns
ns
<
0.
00
0
66 
 
Figure 11. Nocturnal changes in clot formation time as measured by PFA-100. Mean±SD. 
 
 
 
 
* P<0.001 GDM vs. NPCs, P<0.05 PCs vs. NPCs 
 
 
 
Correlation analyses 
 
We found no statistically significant correlations between NA concentrations and coagulation 
variables. As expected, FVIII and vWF correlated strongly in all groups at all sampling times 
(r=0.66–0.78, p<0.001). Concentrations of AM correlated strongly with vWF:Ag (ρ=0.83, 
p=0.000), vWF:RCo (ρ=0.80, p=0.001) and vWF:CB (ρ=0.68, p=0.010) as well as with FVIII:C 
(ρ=0.82, p=0.003) in NPCs. However, these associations did not exist in either of the pregnant 
groups.    
 
 
 
    * 
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Sub-analysis of women with GDM with and without hypertension 
 
In a sub-analysis, we compared, within the GDM group, women with essential hypertension (n=18, 
44%) with those having normal BP (n=23). The differences observed are shown in Table 10. No 
differences existed in measurements of sympathetic activity (NA, HRV) or in levels of AM between 
the groups. Insulin concentrations were higher in subjects with hypertension at midnight but not 
thereafter. Concerning subclinical inflammatory markers, SHBG concentrations were lower and 
AGP levels higher in hypertensive subjects, but statistical significance between the groups was 
reached only at 24 h. In the coagulation analyses, fibrinogen levels were elevated in hypertensive 
women at all time points and APTT was shorter at 4 h. 
 
 
Table 10. Observed differences between subjects with gestational diabetes with and without 
hypertension. Mean (SD). 
 
 
 
Variable GDM with   
hypertension 
GDM with normal 
BP 
p-value 
 
 
Insulin (mmol/l) 
24 h 
4 h 
7 h 
 
 
18.2 (8.1) 
13.8 (3.6) 
13.4 (5.7) 
 
 
12.5 (8.1) 
12.5 (7.2) 
11.7 (5.9) 
 
 
<0.05 
0.49 
0.39 
 
SHBG (nmol/l) 
24 h 
4 h 
7 h 
 
197.6 (67.0) 
200.4 (46.7) 
210.1 (46.0) 
 
238.8 (34.3) 
226.1 (33.6) 
234.6 (28.4) 
 
<0.05 
0.07 
0.06 
 
AGP (mg/l) 
24 h 
4 h 
7 h 
 
593.6 (74.9) 
571.2 (70.3) 
587.1 (78.6) 
 
525.1(114.8) 
520.2 (116.8) 
526.5 (125.2) 
 
<0.05 
0.13 
0.1 
 
Fibrinogen (g/l) 
24 h 
4 h 
7 h 
 
7.9 (1.1) 
7.5 (1.1) 
7.9 (1.0) 
 
6.8 (1.4) 
6.8 (1.0) 
6.8 (0.9) 
 
<0.05 
0.05 
<0.001 
 
APTT (s) 
24 h 
4 h 
7 h 
 
24.9 (2.6) 
24.7 (1.3) 
24.6 (2.3) 
 
25.5 (1.9) 
25.7 (1.5) 
26.9 (6.7) 
 
0.5 
<0.05 
0.2 
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DISCUSSION 
Sympathetic nervous system in gestational diabetes 
Autonomic nervous system dysfunction (mostly interpreted as overactivation of the SNS) has been 
considered to be one of the main contributors to the development of CVD (Mueller et al. 2007, 
McNicholas et al. 2007), and this study was established in order to investigate SNS activity in 
GDM. We found no difference in NA concentrations in GDM compared with normal pregnancy 
although the NA temporal profiles were somewhat different.  Both pregnant groups showed 
comparable increases in NA concentrations during the early morning hours, whereas no such 
increase was seen in non-pregnant healthy women. In HRV analysis, comparably reduced total 
variability was seen in both pregnant groups in comparison with the non-pregnant state. These 
results indicate, firstly, an early morning increase in overall sympathetic activation and withdrawal 
of parasympathetic modulation of the heart during pregnancy, and, secondly, the applicability of 
HRV analysis as a mirror of overall SNS activity during pregnancy.  
 
An increase in NA concentrations towards morning in normal pregnancy has been demonstrated 
earlier (Kaaja et al. 1999). Concerning differences in SNS activity in GDM compared with normal 
pregnancy, only a few studies can be found. Sánches-Margalet et al. found increased concentrations 
of NA in a single measurement in a fasting blood sample after supine rest for 30 minutes in 12 
women with GDM, who were compared with 11 women with normoglycaemic pregnancy 
(Sanchez-Margalet et al. 1998). Concentrations of NA in their work were approximately 3 times 
higher than ours in GDM and 5-fold in subjects with normal pregnancy. In addition to differences 
between NA assessment methods used, this difference could be explained by greater activity of the 
SNS in women studied daytime, but possibly also (at least to some degree) by physical activity and 
other stresses during the day. 
 
Weissman et al. studied 12 women with GDM and 15 pregnant women with normal OGTT results, 
before and after a 100-g OGTT, and found in 10-minute ECG recordings a higher LF/HF ratio in 
the GDM group at baseline (Weissman et al. 2006). Ten-minute ECG recordings were also used in 
51 women with GDM and 28 with normal pregnancies in a study by Heiskanen et al. They found 
higher LFnu and LF/HF in the 3rd trimester than postpartum in all subjects, with no difference 
between GDM and normal pregnancy. They concluded that GDM does not result in cardiovascular 
dysfunction when it is in good balance (Heiskanen et al. 2010). In contrast, Gasic et al. 
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demonstrated reduced HRV in women with a history of GDM one year after pregnancy during both 
daytime and at night (Gasics et al. 2007).  
 
Our results are in concordance with those of Heiskanen et al. in that GDM is not associated with 
reduced HRV compared with normal pregnancy. However, we did not find any differences in 
frequency domain values. Although reduced time domain indices in HRV are generally accepted as 
measures of SNS activation (Task Force of the European Society of Cardiology and the North 
American Society of Pacing and Electrophysiology 1996), interpretation of the frequency domain 
indices needs some caution. No general agreement exists on physiological bases of all frequency 
domain indices. HF power is agreed to represent parasympathetic activity, but the nature of LF is 
more controversial.  LF is considered by some (Malliani et al. 1991, Kamath and Fallen 1993, 
Montano et al. 1994) as a marker of sympathetic modulation (especially when expressed in 
normalized units) and by others (Akselrod et al. 1985) as a parameter that includes both sympathetic 
and parasympathetic influences. Based on the latter view, the LF/HF ratio is considered to mirror 
sympathovagal balance or to reflect sympathetic modulation. This rationale has been challenged on 
the basis of studies which have demonstrated that parasympathetic blockade markedly reduces the 
LF component of HRV (Taylor et al. 1998). In our study, no differences were seen in LF/HF 
between any of our study groups or any time-points within the groups, although total variability 
(SDNN, SDANN) showed significant parasympathetic withdrawal in the pregnant groups. Possible 
explanations could be contemporaneous parasympathetic and sympathetic withdrawal in pregnant 
groups and/or increased parasympathetic and sympathetic activation in NPCs. Regardless of the 
physiological interpretation of HF, LF and LF/HF, our finding of loss of natural fluctuation in these 
indices in GDM is of interest.  
 
Increased circulating NA levels can modulate cardiac autonomic regulation in healthy subjects 
(Tulppo et al. 2005) and somewhat different NA temporal profiles between the GDM and PC 
groups could explain, at least partly, the difference in cardiac ANS modulation. A more likely factor 
behind this difference, however, is pre-diabetic status of women with GDM.  
 
Our finding could indicate early disturbance of autonomic neural control in GDM. Reduced 
variation could precede apparent changes in HRV seen in diabetic patients (Vinik et al. 2007). 
Indeed, this hypothesis is supported by a study concerning postprandial thermogenesis (PPT) and 
NA responses to a meal in women with a history of GDM. The SNS is thought to play an important 
role in regulating PPT (Astrup et al. 1989). In a study by Kousta et al., no difference existed in the 
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amount of PPT in women with previous GDM compared with women with normal pregnancy, 
although the shape of the PPT curve revealed consistent delay in PPT, insulin, and NA responses to 
a meal in the study group  (Kousta et al. 2002). The authors interpreted this as a metabolic defect 
preceding the reductions in absolute indices in further advanced disease. 
 
Our study was performed in well-standardized resting circumstances, minimizing external factors 
potentially disturbing SNS assessment. In addition, SNS activity was studied by using two different 
methods, which gave synergistic results. The heavy study protocol, which required an overnight 
stay in hospital for both the subject as well as the researcher, limited the number of subjects. This 
was especially seen in healthy non-pregnant women, of whom we were able to recruit only 14. 
Hence the results concerning pregnant vs. non-pregnant women may be considered to be 
preliminary. Unfortunately, we lost one third of the Holter recordings because of technical 
problems, which leaves the possibility that some additional differences could have been seen with a 
greater number of such recordings. 
 
The most effective means of prevention of CVD include lifestyle modification, such as healthy diet 
and regular physical exercise. This may be partly explained via reduction of SNS activity (Bisquolo 
et al. 2005, Amano et al. 2001, O’Dea et al. 1982). While waiting for further evidence on the 
efficacy of diet and exercise on the incidence of GDM and long-term health of these women, a 
healthy lifestyle should be encouraged in all women with GDM.  
 
Inflammation 
 
Inflammation represents a physiological process maintaining tissue homeostasis and comprising 
complex crosstalk between different biological systems making use of messengers to hasten 
(positive feedback) and attenuate (negative feedback) the process. In healthy individuals, this chain 
of events generates intra-individual variation/fluctuation of various participating hormones and 
proteins. In early stages of certain diseases, this sensitive feedback system may be disturbed long 
before clinical signs and symptoms of the disease appear. Interest concerning the role of low-grade 
tissue inflammation in CVD has been focused mainly on long-term changes in levels of 
inflammatory markers: CRP has been found a strong independent predictor of adverse cardiac 
events and death both in patients with heart disease as well as in apparently healthy men and 
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women (Ridker et al. 1997). Short-term variation in the concentrations of inflammatory markers has 
not received attention in this respect.  
 
As expected, we found increased low-grade tissue inflammation in pregnant vs. non-pregnant 
women. No differences were found in the concentrations of inflammatory cytokines in GDM vs. 
normal pregnancies. However, nocturnal variation of CRP was significantly smaller in cases of 
GDM than in normal pregnancy. Concentrations CRP remain relatively stable over long periods of 
time (Ridker et al. 2007)and they lack systematic diurnal variation in healthy individuals eier-
wert et al	

. The magnitude of variation observed among women in our study was 
comparable to that reported previously (Meier-Ewert et al. 2001).  
 
In general, the sources of short-term variation of biological agents are assumed to be external to the 
workings of the organism – temperature, food ingestion, physical activity etc. Advanced analysis of 
some serial data on naturally varying agents has suggested that the source of biological variation is 
endogenous rather than exogenous and that it encompasses deterministic behaviour (Kroll et al. 
1999). Our finding of reduced nocturnal variability of CRP, and SAA, suggests disturbance in 
regulation of inflammatory homeostasis in GDM and this may provide new information regarding 
the role of inflammatory markers in the underlying pathogenesis. Reduced (nocturnal) variability 
could precede sustained increases of these inflammatory factors and indicate a need for immediate 
action against overt low-grade tissue inflammation and its possible deleterious consequences. In the 
light of the results on attenuated heart ANS modulation presented above, this hypothesis (and the 
need for preventive actions) becomes more substantial.  
 
Moxonidine, an imidazoline receptor agonist, decreases blood pressure by inhibiting central 
nervous sympathetic activity (Ernsberger et al. 1997, Wenzel et al. 1998). Through this mechanism, 
moxonidine has been suggested to improve insulin sensitivity in hypertensive overweight 
postmenopausal women (Kaaja et al. 2007). We investigated, in that study, the effect of moxonidine 
on low-grade tissue inflammation. Ideally, as regards this thesis, such a study would have been 
performed in our pregnant women with and without GDM. However, the use of moxonidine is 
contraindicated during pregnancy. Similarly as younger women with GDM, postmenopausal 
overweight hypertensive women are at an increased risk of CVD. Thus there is a rationale for  
applying the results in both groups. 
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We found favourable changes in the inflammatory profile in women who had used moxonidine for 
8 weeks compared with those taking the β-blocking agent atenolol. In the moxonidine group, 
concentrations of TNFα were reduced and those of adiponectin remained unchanged, whereas in the 
atenolol group levels of TNFα increased and those of adiponectin decreased dramatically. These 
findings indicate, primarily, that centrally acting sympatholytic agents may be beneficial in 
treatment of postmenopausal women with hypertension and clustering of multiple risk factors for 
CVD. Secondly, they strengthen the earlier view that SNS and inflammation are tightly connected.  
 
While all medication calls for careful consideration during pregnancy, a healthy lifestyle is of 
importance for the mother or the child. SNS activity can be reduced by regular physical exercise 
and diet and, according to our results, reduction in SNS activity might affect low-grade tissue 
inflammation. These changes, in turn, could affect the pathopysiology of GDM. Indeed, the risk of 
GDM has been shown to be inversely proportional to the degree of physical activity before and 
during pregnancy (Tobias et al. 2011). Thus regular daily exercise should be recommended for all 
pregnant women (Hegaard et al. 2007).     
 
Coagulation 
 
Our results confirmed the well-known fact that pregnancy is a state of hypercoagulation. In a large 
epidemiological study, women diagnosed with GDM were at 4-fold higher risk for VTE during 
pregnancy when compared to women with normal glucose tolerance (Jacobsen et al. 2008). The 
mechanisms behind this observation are unknown. Only a few studies have examined coagulation 
in women with GDM, and the results have been somewhat controversial. Women with GDM have 
been found to exhibit elevated PAI-1 levels compared with women with normal pregnancies 
(Akinzi et al. 2008), whereas other investigators have not found such a difference (Winzer et al. 
2004, Bellart et al. 1998). One study revealed higher levels of tissue plasminogen activator, D-
dimer and thrombin-antithrombin complexes as well as lower levels of proteins C and S, 
suggesting increased coagulation and decreased anticoagulation activity in GDM (Bellart et al. 
1998). In a recent study of 150 women with GDM and 100 normoglycaemic controls, Abdel et al. 
found higher fibrinogen as well as protein S levels in cases of GDM (Abdel et al. 2010).  
 
We found no differences in the concentrations of the coagulation parameters studied between the 
GDM and the normal pregnancy group, with the exception of lower FVIII:C in the GDM group. 
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FVIII participates in coagulation via the contact activation pathway, together with coagulation 
factors I, II, V, IX, XI and XII. APTT mirrors the synergy of these factors. We found a small early 
morning increase in APTT, suggesting prolongation of endothelial-associated coagulation and 
slightly increased TT, suggesting weakened fibrin formation in cases of GDM compared with 
normal pregnancy. In addition, slightly lower vWF levels in subjects with GDM were seen. 
Together, these findings indicate attenuation of the contact activation pathway in GDM – an 
observation not supporting a role of a contact activation pathway behind increased VTE risk in 
GDM (Jacobsen et al. 2008). Of interest is the positive correlation between NA and APTT found 
in this study, suggesting an association of the SNS with the contact activation pathway of 
coagulation.   
 
To our knowledge, there is only one published study assessing FVIII in pregnancies complicated 
by GDM. Scholtes and co-workers found an increased FVIII antigen/activity ratio in GDM, but 
only after 32 weeks of pregnancy (Scholtes et al. 1983). As the duration of pregnancy in our 
subjects was shorter, the results are not quite comparable. The lower FVIII:C values observed in 
this study may be due to somewhat lower vWF levels, since vWF is the carrier of FVIII. One 
possibility as regards the decreased amounts of these endothelial coagulation factors could be 
increased consumption during pregnancy, especially in GDM, but this presumption remains to be 
investigated. As vWF is considered to reflect impaired endothelial function, our results speak 
against endothelial impairment in GDM, at least in our study population. Considering the strong 
association between AM and vWF in non-pregnant subjects, discussed below, dissociation of the 
AM-vWF axis during pregnancy could suggest a role of AM in decreased levels of FVIII and vWF 
in pregnancy vs. the non-pregnant state. 
 
Adrenomedullin is expressed by endothelial cells, the intensity of expression being dependent on 
the degree of haemodynamic shear stress. It is thus suggested to have a role in local modulation of 
vascular tone and regulation of coagulation (Marutsuka 2003). This role seems to be 
antithrombotic, based on previous findings demonstrating the inhibitory action of AM on 
expression of TF and PAI-1 (Sugano et al. 2001) and an increasing effect on tissue factor pathway 
inhibitor (Sugano et al. 2001, Liu et al. 2007). Adrenomedullin levels are elevated in normal 
pregnancy (Wilson et al. 2004), which was also demonstrated in this study. No difference in AM 
levels was seen between normal and GDM pregnancies. This is in concordance with results 
published by Di Iorio et al. (Di Iorio et al. 2001). We found a remarkably strong positive 
correlation between AM and both quantitative and qualitative vWF markers in non-pregnant 
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healthy women, a finding compatible with an earlier view that AM is a relevant regulatory factor 
in human coagulation. However, these correlations were lost during pregnancy. The dissociation 
of the AM-vWF axis during pregnancy may be added to earlier findings of aberrant regulation of 
coagulation during gestation. The precise mechanisms and significance behind this finding, 
however, remain to be elucidated.   
 
Elevated circulating levels of catecholamines increase platelet activity both in vitro and in vivo 
(Clayton et al. 1963, O´Brien 1963, Anfossi and Trovati 1996, Mustonen et al. 1996, Westerbacka 
et al. 2002). Even though platelets were more activated at midnight in our pregnant subjects, 
platelet activity seemed to attenuate, not increase, with increasing NA levels towards the morning. 
In addition, we found no correlation between NA and platelet function. A possible explanation for 
these contradictory findings could be higher insulin concentrations during pregnancy. Insulin is 
known to interfere with NA action in the central nervous system (Robertson et al. 2010). In 
addition, it attenuates crucial steps in thrombus formation (Westerbacka et al. 2002). Finally, 
insulin has been shown to increase PFA-100 clotting time (Westerbacka et al. 2002). In the present 
study, pregnant women had higher insulin concentrations than the NPCs. Insulin could, therefore, 
through platelets, serve as a beneficial protective factor against thrombus formation during 
pregnancy.  
 
Gestational diabetes with and without hypertension 
 
GDM and hypertensive disorders of pregnancy (pregnancy-induced hypertension, pre-
eclampsia) are associated, one increasing the occurrence of the other (Landon et al. 2009, 
Benley-Lewis 2009). Hypertension is associated with insulin resistance and hyperinsulinaemia 
(Whaley-Connel and Sowers 2009), changes in levels of inflammatory cytokines (Liu et al. 
1996, Chae et al. 2001, Peeters et al. 2001) and changes in markers of coagulation and 
fibrinolysis (Lee 1997, Poli et al. 2000). These findings support the clinical association between 
hypertension and metabolic disorders and increased risk of thromboembolic complications 
(Gress et al. 2000, Felmeden and Lip 2005). Our results are in concordance with these findings; 
we found higher levels of insulin and increased insulin resistance (lower concentrations of 
SHBG) as well as higher concentrations of AGP in women with GDM combined with 
hypertension. However, these differences seemed to disappear towards the morning. One 
possible explanation for this phenomenon could be physiological diurnal changes during the 
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early morning hours (e.g. increased cortisol secretion, activation of the SNS) which may 
interfere and/or mask the underlying differences.  
 
SHBG has been demonstrated to be a strong independent risk factor of the development of T2D 
in women (Lindstedt et al. 1991). Recent genetic studies indicate that SHBG and sex hormones 
are also involved in the aetiology of type 2 diabetes (Ding et al. 2006, Perry et al. 2010). Thus, 
lower serum SHBG concentrations in GDM, combined with hypertension, could indicate an 
increased risk of T2D in these women. Earlier studies on SHBG in GDM as well as in 
hypertensive pregnancy complications have, however, shown controversial results (Thomann et 
al. 2008, Spencer et al. 2005, Kopp et al. 2001, Mc Eldruff et al. 2005, Yu et al. 2004, Wolf et 
al. 2002). 
 
The presence of elevated concentrations of fibrinogen in hypertensive women with GDM in this 
study is in concordance with earlier findings in hypertensive non-pregnant subjects (Lee 1997). 
The absence of other differences in the studied coagulation parameters could be explained by 
young age and relatively mild hypertension in our study subjects, since the degree of a 
prothrombotic state has been shown to correlate with the degree and duration of hypertension 
(Lip and Blann 2000). Another explanation may be the small number of subjects in the sub-
study. 
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CONCLUSIONS 
 
The occurrence of GDM during pregnancy is an important risk factor for later development of T2D 
and CVD. Understanding the pathophysiology of GDM could give us tools for primary prevention, 
because the delay in the development of T2D and CVD after GDM may be decades. The present 
study was aimed at investigation of the  possible role of the SNS in GDM and the association of the 
SNS with insulin, AM, low-grade tissue inflammation and coagulation.  
 
The results indicated  
 
1. Similar overall SNS activity but disturbed heart SNS modulation (as evidenced by 
reduced rhytmicity of HRV) in GDM compared with normal pregnancy.   
 
2. Comparable low-grade tissue inflammation in GDM and normal pregnancy without 
uniform associations between NA and the studied cytokines. Decreased nocturnal 
variation of CRP concentrations in GDM vs. normal pregnancy. 
 
 
3. Lower FVIII:C in GDM than in normal pregnancy; no significant correlations between 
NA and coagulation variables. 
 
4. Beneficial effect of central inhibition of the SNS with moxonidine on low-grade 
inflammatory profile in postmenopausal overweight hypertensive women.  
 
 
Our results thus did not support our a priori hypothesis of increased SNS activity, low-grade tissue 
inflammation and enhanced coagulation in GDM. Nor did they support straight associations 
between the SNS, inflammation and coagulation. Measurement of a large number of different 
variables revealed an interesting finding showing reduced nocturnal variation in HRV frequency 
domain indices, CRP, SAA and insulin in GDM. A new hypothesis was set: GDM is associated 
with early disturbance of autonomic and humoral control that may precede apparent changes with 
advancing disease, i.e. transition of GDM to T2D (Figure 12). If this hypothesis, in the future, 
proves valid, further understanding of the regulatory mechanisms could provide new strategies for 
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prevention of metabolic diseases after GDM. Our results support incorporation of the SNS as one of 
the targets in this battle. 
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Figure 12. 
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